Document:

Exhibit 10.18

 

 

CERTAIN IDENTIFIED INFORMATION, MARKED
BY [***], HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO
THE COMPANY, IF PUBLICLY DISCLOSED.

 

 

 

 

 

 

 

 

 

LENZILUMAB

 

 

 

LICENSE AGREEMENT

 

 

 

AMONG

 

 

 

HUMANIGEN, INC.

 

 

 

KPM TECH CO., LTD.

 

 

 

AND

 

 

 

TELCON RF PHARMACEUTICAL, INC.

 

 

 

 

 

 

 

DATED: 3 NOVEMBER 2020

 

    	CONFIDENTIAL		 
	 	 	 

    	 

    

 

CONTENTS

 

	Section	 	Title	 	Page
	 	 	 	 	 
	1	 	Definitions	 	1
	 	 	 	 	 
	2	 	Grant of Rights	 	1
	 	 	 	 	 
	3	 	Supplies of the Licensed Product	 	3
	 	 	 	 	 
	4	 	Compensation	 	4
	 	 	 	 	 
	5	 	Records; Reports; Audit	 	5
	 	 	 	 	 
	6	 	Development and Commercialization by Licensee	 	6
	 	 	 	 	 
	7	 	Regulatory Matters	 	8
	 	 	 	 	 
	8	 	Confidentiality	 	10
	 	 	 	 	 
	9	 	Representations and Warranties	 	11
	 	 	 	 	 
	10	 	Indemnification	 	13
	 	 	 	 	 
	11	 	Limitation of Liability	 	13
	 	 	 	 	 
	12	 	Proprietary Rights	 	14
	 	 	 	 	 
	13	 	Term and Termination	 	15
	 	 	 	 	 
	14	 	General Provisions	 	17
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	Exhibit	 	Title	 	Page
	 	 	 	 	 
	A	 	Definitions	 	A-1
	 	 	 	 	 
	B	 	Licensed Patents	 	B-1
	 	 	 	 	 
	C	 	Licensed Know-How and Licensed Copyrights	 	C-1
	 	 	 	 	 
	D	 	Licensed Trademarks	 	D-1
	 	 	 	 	 
	E	 	Licensed Product 	 	E-1
	 	 	 	 	 
	F	 	Compensation for License	 	F-1
	 	 	 	 	 
	G	 	Retention of Exclusivity Requirements	 	G-1
	 	 	 	 	 
	H	 	Specific Diligence Requirements	 	H-1
	 	 	 	 	 
	I	 	Insurance Requirements	 	I-1
	 	 	 	 	 
	J	 	Content for Public Announcements	 	J-1
	 	 	 	 	 
	K	 	Key Terms of Supply Agreement	 	K-1

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE i
	 	 	 

    	 

    

 

LICENSE AGREEMENT

 

This
License Agreement (this “Agreement”) is made this 3rd day of November, 2020 (the “Effective
Date”) among:

 

HUMANIGEN,
INC., a Delaware corporation with offices at 533 Airport Blvd, Ste 400, Burlingame, CA 94010, USA (“HGEN”);

 

KPM TECH CO., LTD., a South
Korean corporation (KOSDAQ: 042040) with offices at 122, Sandan-ro 163beon-gil, Danwon-gu, 15429, South Korea (“KPM”);
and

 

TELCON RF PHARMACEUTICAL, INC.,
a South Korean corporation (KOSDAQ: 200230) with offices at 54, Gongse-ro, Giheung-gu, 17086, South Korea (“Telcon”).

 

KPM and Telcon are individually and collectively
referred to herein as the “Licensee”. HGEN and Licensee are individually referred to herein as a “Party”
and are collectively referred to herein as the “Parties”.

 

Recitals

 

Whereas,
HGEN owns or controls the Licensed Rights (defined below); and

 

Whereas,
Licensee desires to obtain a license under the Licensed Rights to develop and commercialize the Licensed Product for the Licensed
Indication in the Territory (as such terms are defined below), and HGEN is willing to grant such license to Licensee, under the
terms and conditions set forth herein.

 

Now,
Therefore, in consideration of the following mutual promises and other good and valuable consideration, the receipt
and sufficiency of which is acknowledged, the Parties, intending to be legally bound, agree as follows:

 

		1	DEFINITIONS.

 

Certain defined terms
used in this Agreement shall have the meanings respectively given to them in Exhibit A hereto.

 

		2	GRANT OF RIGHTS.

 

		2.1	License from HGEN to Licensee.

 

		(a)	Grant of License. Subject to the terms and conditions of this Agreement, including but not
limited to payment of the amounts set forth in Section 4 below, HGEN hereby grants to Licensee a nontransferable (except with respect
to the assignment provisions in Section 14.13) license during the Term under the Licensed Rights solely:

 

		(i)	to develop the Licensed Product; and

 

		(ii)	to register, use, market, distribute, sell, offer for sale, import, and otherwise commercialize
the Licensed Product;

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 1
	 	 	 

    	 

    

 

in the Territory solely for the
Licensed Indication. Licensee may not sublicense the Licensed Rights, except as expressly set forth in Section 2.1(d) below.

 

		(b)	Exclusivity of License. The license provided under Section 2.1(a)(i) shall be non-exclusive.
The license provided under Section 2.1(a)(ii) shall be:

 

		(i)	exclusive, for the Territory, for so long as Licensee is in compliance with the relevant exclusivity
requirements of Exhibit G hereto; and

 

		(ii)	non-exclusive, for the Territory, if HGEN elects to convert the exclusive license to non-exclusive
pursuant to Exhibit G hereto if Licensee at any time is not in compliance with the relevant exclusivity requirements of
Exhibit G hereto.

 

For clarity, if the rights of Licensee
for the Territory become non-exclusive pursuant to clause 2.1(b)(ii), such rights shall not again become exclusive without the
written agreement of HGEN, which shall be in the discretion of HGEN. Notwithstanding the foregoing, to the extent that any Licensed
Rights are licensed to HGEN or its Affiliates by a third party on a non-exclusive basis, the license granted to Licensee under
this Agreement shall be exclusive as to HGEN and non-exclusive as to any third party.

 

		(c)	Scope of License. Licensee further undertakes and agrees that:

 

		(i)	the Licensed Rights do not include the right to manufacture the Licensed Product;

 

		(ii)	the Licensed Rights do not include rights for indications which are not included in the Licensed
Indication;

 

		(iii)	HGEN retains rights to research, develop and commercialize products other than the Licensed Product
and the Licensed Product for fields and indications other than the Licensed Indication; and

 

		(iv)	HGEN shall not be liable to Licensee for violation of Licensee’s exclusive rights hereunder
by parties which are not Affiliates of HGEN.

 

		(d)	Sublicensing. Licensee shall have the right to grant sublicenses under the Licensed Rights
to the following parties (collectively “Sublicensees”):

 

		(i)	Licensee’s Affiliates (without the approval of HGEN); and

 

		(ii)	other parties which are not Licensee’s Affiliates only with the written approval of HGEN
(which HGEN may provide or withhold in its discretion);

 

under the licenses granted to Licensee
pursuant to this Section 2.1; provided that Licensee warrants and shall procure, as a condition precedent thereto,
that each such Sublicensee shall be advised of, comply with, and enter into an agreement (in a form reasonably satisfactory to
HGEN, with HGEN named as an intended third-party beneficiary) with Licensee pursuant to which it shall acknowledge and agree to
observe and be bound by the applicable restrictions set forth in this Agreement. Licensee shall be responsible and liable for any
breach of this Agreement by a Sublicensee on the same basis as a breach of this Agreement by Licensee. Other than as specifically
provided in this Section 2.1(d), Licensee shall not have the right to grant sublicenses to any person or entity under the
license granted pursuant to this Section 2.1. Such Sublicensees shall not have the right to further sublicense the Licensed
Rights.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 2
	 	 	 

    	 

    

 

		2.2	License from Licensee to HGEN. Subject to Section 2.3(a), Licensee agrees that HGEN shall
have the non-exclusive, transferable, perpetual, worldwide and royalty-free right, with the right to grant sublicenses (through
multiple tiers of sublicensees), to use Improvements (including without limitation Licensee’s and its Affiliates’ and
Sublicensees’ rights therein) not solely owned by HGEN pursuant to Section 12.1(b) to make, have made, use, market, distribute,
sell, offer for sale, import and otherwise research, develop and commercialize products formulated with lenzilumab and other products.
For clarity, the rights of HGEN under this Section 2.2 shall be subject to HGEN’s obligations under Section 2.3(a).

 

		2.3	Exclusivity Commitments. To fairly and properly value the license of the Licensed Rights
pursuant to this Agreement and confirm the diligence obligations of Licensee hereunder, the Parties undertake and agree as follows:

 

		(a)	HGEN Commitment. For such time during the Term while Licensee enjoys exclusive rights pursuant
to Section 2.1(b), HGEN and its Affiliates will not, directly or indirectly, commercialize, or grant any third party the right
to commercialize, a product for the Licensed Indication in the Territory containing lenzilumab as an active ingredient (for clarity,
research and development uses of lenzilumab by HGEN, its Affiliates and their permitted licensees are not restricted by this Agreement).

 

		(b)	Licensee Commitment. During the Term and for a period of two (2) years thereafter, Licensee
and its Affiliates and Sublicensees will not research, develop or commercialize, or grant any third party the right to research,
develop or commercialize, a product containing lenzilumab as an active ingredient (for the Licensed Indication or any other indication),
other than the Licensed Product for the Licensed Indication during the Term pursuant to this Agreement.

 

		(c)	Unauthorized Sales. Licensee and its Affiliates and Sublicensees will not promote, market,
distribute, export, or sell the Licensed Product outside of the Territory or outside of the Licensed Indication, including without
limitation (i) Internet or online sales to customers outside of the Territory, or (ii) for indications not included in the Licensed
Indication.

 

		2.4	Transaction Approvals. Licensee represents and warrants to HGEN as of the Effective Date
that no approvals are required under Applicable Laws by any governmental or regulatory authority in the Territory for the execution
or effectiveness of this Agreement or for the remittance of payments by Licensee to HGEN hereunder. In the event that any such
approvals are imposed or required after the Effective Date, Licensee at its cost shall obtain such approvals.

 

		3	SUPPLIES OF THE LICENSED PRODUCT.

 

		3.1	General. Subject to the terms and conditions hereunder, (i) HGEN shall supply the Licensed
Product exclusively to Licensee in the Territory for the Licensed Indication, and (ii) HGEN shall be the exclusive supplier of
Licensee’s requirements of the Licensed Product, pursuant to Section 3.2 below and the Supply Agreement to be entered into
by and between the Parties, including matters set forth in Exhibit K.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 3
	 	 	 

    	 

    

 

		3.2	HGEN Alternatives. Licensee’s requirements for supplies of the Licensed Product shall
be satisfied by one or more of the following alternatives:

 

		(a)	Supplies by HGEN. Unless Section 3.2(b) applies, HGEN shall supply the Licensed Product
pursuant to the Supply Agreement.

 

		(b)	HGEN Contract Manufacturers. HGEN in its discretion may designate Licensee as an approved
purchaser to one or more suppliers of the Licensed Product which operate under license from HGEN (each a “HGEN Contract
Manufacturer”), so that (i) Licensee may directly provide forecasts, issue purchase orders, receive deliveries and pay
for the Licensed Product, and/or (ii) Licensee and such HGEN Contract Manufacturer(s) may negotiate a direct supply agreement for
the Licensed Product. (For clarity, Licensee acknowledges that such HGEN Contract Manufacturer(s) may be under an obligation to
pay royalties or other compensation to HGEN or its Affiliates related to supplies of the Licensed Product sold to Licensee.)

 

The terms and conditions specified
in Exhibit K shall apply for supplies of the Licensed Product by HGEN pursuant to Section 3.2(a) or by HGEN Contract Manufacturers
pursuant to Section 3.2(b), as supplemented by mutually agreed terms in the Supply Agreement or the standard terms and conditions
of the relevant HGEN Contract Manufacturer.

 

		4	COMPENSATION.

 

		4.1	Compensation for License. Licensee shall compensate HGEN as specified in Exhibit F
attached hereto for the rights licensed by HGEN to Licensee and other obligations of HGEN pursuant to this Agreement.

 

		4.2	Currency. All amounts due hereunder are stated in, and shall be paid in, U.S. dollars. Net
Sales based on foreign revenue will be converted to U.S. dollars at the rate of exchange published in The Wall Street Journal,
Digital Edition on the last day of each calendar quarter. Licensee shall provide HGEN, together with each royalty payment, a schedule
detailing the calculation of Net Sales resulting from the conversion of foreign revenue to U.S. dollars as set forth herein.

 

		4.3	Taxes. Each Party shall be responsible for its own taxes, including the income taxes on
its business and, and other taxes incurred by such Party in connection with its business and with performing its obligations hereunder,
as follows:

 

		(i)	Delivery of the Licensed Products shall be made on an EX WORKS (EXW) basis outside of the Territory.
Licensee shall pay any VAT (if applicable for export sales) and other transfer taxes for the sale of the Licensed Products to Licensee,
and duties (including customs duties) for the import of the Licensed Products into the Territory.

 

		(ii)	Licensee shall be solely responsible for any application fees, user fees, or other regulatory assessments
payable in the Territory based on Licensee’s performance of this Agreement.

 

		(iii)	HGEN shall be solely responsible for income taxes and any other taxes and duties payable in the
USA based on HGEN’s performance of this Agreement.

 

		(iv)	Licensee shall be solely responsible for income taxes and any other taxes and duties payable in
the Territory based on Licensee’s performance of this Agreement.

 

		(v)	If Applicable Laws in the Territory require the withholding of taxes on payments from Licensee
to HGEN hereunder, Licensee shall subtract the amount thereof from such payments and shall remit such withheld amount to the relevant
governmental authority in a timely manner. For the avoidance of doubt, for any payment due to HGEN hereunder, Licensee’s
remittance of such withheld taxes to the relevant governmental authority, together with remittance to HGEN of the remaining balance
of such payment, shall constitute Licensee’s full satisfaction of such payment obligation. Licensee shall submit to HGEN
appropriate proof of payment of the withheld taxes within ten (10) calendar days after remittance to such governmental authority.
The Parties shall reasonably cooperate to eliminate or minimize any such withholding taxes, to the extent permitted by and in full
compliance with Applicable Law.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 4
	 	 	 

    	 

    

 

Licensee shall provide HGEN with
official receipts to confirm that such taxes have been paid.

 

		4.4	Late Payments. Unpaid balances shall accrue interest, from the due date until paid, at a
rate equal to the greater of (i) the prime rate, as reported in The Wall Street Journal, Digital Edition, on the date
such payment is due, plus an additional two percent (2%) per annum, or (ii) twelve percent (12%) per annum; provided that
such rate shall not exceed the maximum rate permitted under Applicable Law.

 

		5	RECORDS; REPORTS; AUDIT.

 

		5.1	Records. During the Term and for a period of one (1) year thereafter, Licensee shall, and
shall require its Affiliates and Sublicensees to, maintain complete and accurate records relating to (i) progress made toward
achievement of the milestones set forth in Exhibit F hereto, (ii) Net Sales of the Licensed Product, and (iii) all tax payments
pursuant to Section 4.3.

 

		5.2	Quarterly Reports. Within thirty five (35) calendar days following the conclusion of each
calendar quarter during the Term, Licensee shall provide HGEN with written reports with respect to such calendar quarter that (i) describe
in reasonable detail Licensee’s progress made toward achievement of the milestones set forth in Exhibit F hereto and
compliance with the requirements of Exhibits G and H hereto during such calendar quarter, including without limitation Licensee’s
non-binding, then-current best estimate for the dates to achieve such milestones, and (ii) set forth in reasonable detail
complete and accurate records of Licensee’s, its Affiliates’ and Sublicensees’ gross sales, Net Sales, and calculations
from gross sales to Net Sales of the Licensed Product in the Territory during such calendar quarter. Licensee will make every effort
to provide quarterly reports for actual results but if actual financial results are not available for the quarter, Licensee shall
provide HGEN by such date with (i) actual Net Sales for the first two months of the calendar quarter, and (ii) an estimate of Net
Sales for the third month of the calendar quarter. If Licensee has provided estimated results during the year, Licensee shall include
a reconciliation of the estimated to actual results for each quarter and for the year. Any differences resulting from this reconciliation
shall be included in the mounts owed for the fourth quarter of the year.

 

		5.3	Annual Reports. Annually, within sixty (60) days from the end of each calendar year during
the Term, Licensee shall provide HGEN with written reports that: (i) summarize in reasonable detail Licensee’s communications
and meetings with any regulatory authority related to the Licensed Product during the prior calendar year; (ii) provide HGEN
with Licensee’s non-binding, reasonable, estimated rolling projection for sales of the Licensed Product in the Territory,
in terms of volume quantities and Net Sales values on a country-by-country basis, for the current year and next two (2) calendar
years; and (iii) set forth such other information as mutually agreed upon by the Parties. Licensee will make every effort
to provide full annual reports of actual results within sixty (60) calendar days following the conclusion of each calendar year
during the Term. Such annual reports shall be in addition to the quarterly reports required by Section 5.2.

 

		5.4	Audit. During the Term and for a period of one (1) year thereafter, HGEN shall have the
right, no more frequently than once per year and only during normal business hours and upon reasonable advance notice (which shall
be given no less than thirty (30) days), to inspect and audit by an independent qualified outside auditor (utilizing the Korean
affiliate of a global accounting firm) Licensee’s and its Affiliates’ and Sublicensees’ records relevant to (i) progress
made toward achievement of the milestones set forth in Exhibit F hereto and compliance with the requirements of Exhibits
G and H hereto, (ii) Net Sales, and (iii) compliance with the provisions of this Agreement. The costs of such audits shall
be borne solely by HGEN; provided, however, that in the event such an audit reveals either a failure by Licensee to pay
any applicable milestone payment due or an underpayment by Licensee of royalties owed hereunder, Licensee shall immediately:

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 5
	 	 	 

    	 

    

 

		(i)	pay HGEN all amounts by which Licensee has underpaid HGEN as revealed by the audit, plus interest
accrued thereon (from the applicable original due date) at the rate set forth in Section 4.4 above; and

 

		(ii)	if such underpayment is more than three percent (3%) of the total due for the relevant period,
reimburse HGEN for the costs of such audit.

 

All audit results, whether or
not the results show a failure by Licensee to pay any applicable milestone payment due or an underpayment by Licensee of royalties
owed hereunder, shall be promptly provided to Licensee. All information concerning royalty payments and reports, and any information
learned in the course of any audit or inspection under this Section 5.4, shall be deemed to be Confidential Information of
Licensee, subject to the terms and provisions of Section 8 below, except to the extent necessary for HGEN to enforce its rights
under this Agreement, and License may require HGEN or any such independent qualified outside auditor to enter into a reasonable
confidentiality agreement prior to allowing access to any information or records subject to audit hereunder.

 

		6	DEVELOPMENT AND COMMERCIALIZATION BY LICENSEE. 

 

		6.1	General. Licensee shall be solely responsible at its cost for the preparation, filing and
obtainment of any regulatory approvals necessary for the commercialization of the Licensed Product for the Licensed Indication
in the Territory, including conducting and funding all development, regulatory and commercialization activities associated with
and specifically for the purposes of obtaining regulatory approvals of the Licensed Product for the Licensed Indication in the
Territory. For clarity, HGEN shall be soley responsible at its cost for the preparation, filing and obtainment of any regulatory
approvals for the commercialization of the Licensed Product outside of the Territory.

 

		6.2	Joint Steering Committee. A joint steering committee (“Joint Steering Committee”)
will be established as a body for discussion and decision-making about all important courses of action affecting the development,
regulatory approval and commercialization of the Licensed Product for the Licensed Indication in the Territory, including without
limitation the creation of, or amendments to, the following plans:

 

		(a)	Development Plan. Licensee shall propose, and the Joint Steering Committee shall discuss,
modify and approve, a development and regulatory approval plan to develop and obtain and maintain regulatory approvals for the
Licensed Product for each country within the Territory (the “Development Plan”). The Development Plan shall
specify in detail required pre-clinical and clinical testing actions, protocols and plans. The initial draft Development Plan shall
be submitted by Licensee to the Joint Steering Committee on or before the date which is six (6) months after the Effective Date
(this period may be changed through mutual discussion by the Parties if this Agreement is amended pursuant to Section 14.9). The
Development Plan shall be updated on an annual basis (within twelve (12) months after the last Development Plan was approved by
the Joint Steering Committee) until regulatory approval of the Licensed Product for each country within the Territory.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 6
	 	 	 

    	 

    

 

		(b)	Launch Plan. Licensee shall propose, and the Joint Steering Committee shall discuss, modify
and approve, a launch plan for each country within the Territory (the “Launch Plan”). The initial draft Launch
Plan shall be submitted by Licensee to the Joint Steering Committee on or before the date which is six (6) months from the Effective
Date (this period may be changed through mutual discussion by the Parties if this Agreement is amended pursuant to Section 14.9),
which may be modified or delayed upon agreement by both Parties. The Launch Plan shall be updated on an annual basis (within twelve
(12) months after the last Launch Plan was approved by the Joint Steering Committee) until the Licensed Product has been launched
in each country within the Territory.

 

		(c)	Commercialization Plan. Licensee shall propose, and the Joint Steering Committee shall discuss,
modify and approve, a commercialization plan for each country within the Territory (the “Commercialization Plan”).
The initial draft Commercialization Plan shall be submitted by Licensee to the Joint Steering Committee on or before the date which
is six (6) months after the Effective Date (this period may be changed through mutual discussion by the Parties if this Agreement
is amended pursuant to Section 14.9), which may be modified or delayed upon agreement by both Parties. The Commercialization Plan
shall be updated on a semi-annual basis (within six (6) months after the last Commercialization Plan was approved by the Joint
Steering Committee).

 

The Joint Steering
Committee shall have a total of six (6) members, with three (3) members appointed by each Party. Each Party may appoint, remove
and replace the three (3) members appointed by such Party from time to time in its discretion. All decisions of the Joint Steering
Committee shall be made by majority vote, with at least one (1) member appointed by each Party voting with the majority. Each Party
shall appoint at least one (i) member who is familiar with both the English and Korean commercial languages. The Joint Steering
Committee shall meet in person or via videoconference or teleconference on a quarterly basis or on such other schedule as may be
required and agreed. Notwithstanding the foregoing, HGEN may in its discretion discontinue the Joint Steering Committee if it determines
that it is no longer necessary.

 

		6.3	Diligence for Development. Licensee shall use, and shall require its Affiliates and Sublicensees
to use, commercially reasonable efforts to develop and obtain and maintain regulatory approvals for the Licensed Product in each
country within the Territory in accordance with Section 7.1 below. Such commercially reasonable efforts shall include without limitation
the actions specified in the then-current Development Plan and Exhibit H. All research (if any is permitted by the amendment
of this Agreement), development and regulatory approval activities shall be conducted by Licensee in accordance with Applicable
Laws and the applicable Development Plan.

 

		6.4	Diligence for Commercialization. Licensee undertakes and agrees to diligently commercialize
the Licensed Product as follows:

 

		(a)	Commercially Reasonable Efforts. Licensee shall use, and shall require its Affiliates and
Sublicensees to use, commercially reasonable efforts to market, promote, and sell Licensed Product in each country within the Territory
after marketing approval is obtained, in an effort to maximize Net Sales, and royalties payable under this Agreement. Such commercially
reasonable efforts shall include without limitation the actions specified in the then-current Product Launch Plan, the then-current
Commercialization Plan, and Exhibit H.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 7
	 	 	 

    	 

    

 

		(b)	Requirements to Maintain Exclusivity. Licensee shall comply with the requirements set forth
in Exhibit G hereto, and in the event of noncompliance thereof, the exclusive rights purusant to Section 2.1(b)(i) provided
to Licensee may, at HGEN’s option pursuant to Exhibit G, be converted to non-exclusive rights pursuant to Section
2.1(b)(ii) for the Territory.

 

		(c)	Specific Diligence Requirements. Licensee shall comply with the requirements set forth in
Exhibit G and Exhibit H hereto, and in the event of noncompliance thereof, HGEN may, at its option pursuant to Exhibit
G, terminate this Agreement pursuant to Section 13.2.

 

		6.5	Costs and Expenses. Licensee shall be solely responsible for all costs and expenses related
to its development, regulatory approval, and commercialization of the Licensed Product within the Territory. Pursuant to the Services
Agreement or otherwise, Licensee shall reimburse HGEN for costs and expenses related to services requested by Licensee, including
without limitation travel expenses for HGEN personnel attending meetings at the request of Licensee.

 

		7	REGULATORY MATTERS.

 

		7.1	Regulatory Approvals. Licensee in its discretion and at its cost shall submit relevant applications
and obtain and maintain regulatory approvals for the Licensed Product for the Licensed Indication in the Territory, including without
limitation any pre-clinical, clinical, regulatory filings, post-approval requirements or commitments, and shall adhere to and fulfill
all commitments, agreements, and promises in Licensee’s regulatory applications and all conditions of the regulatory approvals.
Pursuant to the Applicable Law, Licensee shall during the Term hold and own all regulatory applications and approvals for the Licensed
Product for the Licensed Indication in the Territory. Upon termination of this Agreement, Licensee shall, if requested by HGEN,
assign and transfer all regulatory applications (and amendments and supplements thereto) and approvals for the Licensed Product
for the Licensed Indication in the Territory to HGEN or its Affiliates or Sublicensees in accordance with Section 13.3. Licensee
shall not submit any information for marketing applications or approvals covering the Licensed Product without the written consent
of HGEN. Licensee shall be solely responsible for all communications with regulatory agencies in connection with the Licensed Product
for the Licensed Indication in the Territory, including without limitation determining the suitability and use of documentation
provided by HGEN, subject to Section 7.2. Licensee shall inform HGEN of meetings with regulatory agencies in the Territory regarding
the Licensed Product promptly upon determination of the occurrence of such meetings and shall allow HGEN to participate (if possible)
in any regulatory agency meetings, videoconferences, teleconferences, or other regulatory review regarding the Licensed Product.

 

		7.2	Copies of Regulatory Information. Licensee shall provide HGEN with copies of all regulatory
submissions and correspondence, and minutes or summaries of regulatory interactions, and other communications relating to the Licensed
Product, within thirty (30) days of receipt or submission, or the date of such meeting or other communication. If HGEN reasonably
determines that any such submission would materially adversely affect the Licensed Product, HGEN shall notify Licensee and the
Joint Steering Committee shall resolve the matter in good faith.

 

		7.3	Cooperation by HGEN. HGEN shall reasonably cooperate and promptly and diligently provide
reasonable assistance as required by the relevant regulatory authority in order for Licensee to obtain and maintain the regulatory
approval of the Licensed Product for the Licensed Indication in the Territory, including providing (i) data and information already
in the possession of HGEN pursuant to Section 7.4 below regarding non-clinical studies, pre-clinical studies, and clinical studies
of the Licensed Product for the Licensed Indication, (ii) samples of the Licensed Product requested solely for purposes of pre-clinical
and clinical studies to be conducted by Licensee at Licensee’s cost in the Licensed Indication in the Territory if such studies
are required by the applicable regulatory authority to apply for regulatory approval for the Licensed Product in the Territory,
(iii) access for regulatory authority’s inspections of HGEN’s facilities and HGEN’s contract manufacturing facilities
(including giving access to HGEN’s facilities and facilitating access to HGEN’s contract manufacturing facilities and
providing cooperation for on-site inspection by the regulatory authority prior to and after granting the regulatory approval of
the Licensed Product for the Licensed Indication to ensure the compliance of cGMP and other regulatory requirements applicable
in the Territory), and (iv) any other reasonable requests by Licensee for the purposes of obtaining and maintaining the regulatory
approval of the Licensed Product for the Licensed Indication in the Territory. It is expected that services provided by HGEN under
this section and any additional services requested by Licensee and provided by HGEN shall be governed by the Services Agreement.
For clarity, this Agreement does not require HGEN to undertake any clinical studies of the Licensed Product.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 8
	 	 	 

    	 

    

 

		7.4	Access to HGEN Data. Licensee shall have the right to reference and utilize in the Territory
relevant clinical and regulatory data in HGEN’s possession and HGEN’s regulatory filings (such as US NDA, BLA and/or
EUA) solely for regulatory approval and commercialization of the Licensed Product for the Licensed Indication in the Territory
during the Term. Upon request by Licensee, HGEN shall promptly either make such data directly accessible to the applicable regulatory
authorities such as through a drug master file or provide Licensee with a copy of such data or make such data accessible to Licensee
through such means and at such times and locations as are mutually agreed upon by the Parties. In the event that the relevant regulatory
authority requires any additional and/or supplemental materials and/or information for the purposes of the regulatory approval
of the Licensed Product for the Licensed Indication in the Territory and maintenance thereof, the Parties in good faith shall discuss
the feasibility of, and allocation of costs for, obtaining such additional and/or supplemental materials and/or information.

 

		7.5	Access to Licensee Data. HGEN and its Affiliates and licensees shall have the right to reference
and utilize without charge all toxicology/safety, clinical, patient, regulatory, scientific, technical, formulation, stability,
and other data and regulatory filings relating to the Licensed Product developed or obtained by Licensee and its Affiliates and
Sublicensees. Upon request by HGEN, Licensee shall either provide HGEN with a copy of all such data or shall make such data accessible
to HGEN through such means and at such times and locations as are mutually agreed upon by the Parties. In addition, Licensee shall
provide to HGEN a summary of such data within one (1) month after the completion of any toxicology/safety, clinical, patient, regulatory,
scientific, technical, formulation, stability or other studies or any regulatory filings.

 

		7.6	Adverse Events. Licensee and its Affiliates and Sublicensees shall comply with all Applicable
Laws that relate to the reporting and investigation of adverse events related to the Licensed Product and recordkeeping with respect
thereto, including without limitation developing written procedures for the surveillance, receipt, evaluation, and reporting of
post-marketing adverse experiences and adverse events to the applicable regulatory authority in the Territory. Licensee and its
Affiliates and Sublicensees shall provide HGEN with copies of all reports of such adverse events (with the following time periods
measured from the date of receipt by Licensee, its Affiliate or Sublicensee) within (i) seven (7) calendar days for any serious
adverse experience or serious adverse event as those terms are defined by FDA or (ii) ten (10) calendar days for all other adverse
experiences or adverse events. Licensee shall promptly investigate all safety information it receives, and provide HGEN all data
and information from its investigation (including raw data and correspondence) within ten (10) calendar days of Licensee’s
receipt thereof. During the Term of this Agreement and for a period of one year following termination, Licensee shall also advise
HGEN regarding any proposed labeling or regulatory approval changes affecting the Licensed Product. The PV Agreement supplements
the provisions of this Section 7.6, including without limitation providing information for a global safety database (owned by HGEN
with the cost of such database shared among all users with Licensee paying its proportionate share as a percentage of all quantities
of the Licensed Product sold in the relevant calendar year).

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 9
	 	 	 

    	 

    

 

		7.7	Publications. The Parties acknowledge that it would be beneficial to the advancement of
biomedical research generally and of the science relating to lenzilumab in particular to publish in the Territory information related
to the Licensed Product in the Licensed Indication, with prior review and approval by both Parties. Licensee agrees not to publish
or publicly present any information related to the Licensed Product, without HGEN’s prior written consent, if such information
contains HGEN’s Confidential Information, including without limitation Licensed Know-How. Any other publications or presentations
related to the Licensed Product not containing HGEN’s Confidential Information shall be provided to HGEN at least ten (10)
business days in advance of submission or presentation for HGEN’s review and concurrence, which shall not be unreasonably
withheld.

 

		7.8	Applicable Laws. HGEN and Licensee shall comply with all Applicable Laws related to the
research, development, regulatory approval, sale, and commercialization of the Licensed Product.

 

		8	CONFIDENTIALITY. 

 

		8.1	Definition. As used in this Agreement, “Confidential Information” shall
mean any and all information (including, without limitation, information relating to products, processes, technologies, trade secrets,
structures, ideas, works or authorship, copyrightable works, trademarks, copyrights, product concepts, techniques, information
or statistics, compounds, inventions, know-how, designs, specifications, formulas, methods, samples, biological, chemical or other
materials, developmental or experimental work, improvements, discoveries, past, current, planned and future research and non-clinical
and clinical or other data, patient protected health information (including without limitation individually identifiable health
information, test results, and other data or information used to identify a patient), drug master file, databases, software, manuals,
internal policies and procedures, licenses, research and development agreements, term sheets, prices, costs, financial information,
budgets, projections, marketing, selling and business plans, strategies, forecasts, sketches, records, notes, devices, drawings,
patent applications, continuation applications, continuation-in-part applications, file wrapper continuation-in-part applications
and divisional applications, vendors, suppliers and customers) that either Party (a “Disclosing Party”) furnishes
or otherwise makes available to the other Party (a “Receiving Party”), directly or indirectly, together with
all analyses, compilations, studies or other documents which contain or otherwise reflect or are derived from such information.
Without limiting the generality of the foregoing, HGEN’s Confidential Information includes all materials provided by HGEN
which are Licensed Know-How.

 

		8.2	Non-Disclosure. Each Receiving Party agrees to (i) not disclose, and maintain the confidentiality
of, the Confidential Information of the Disclosing Party, and (ii) limit access to the Confidential Information of the Disclosing
Party to such of its officers, agents, employees, and legal counsel who (A) are directly concerned with the purposes of this Agreement,
and (B) are subject to confidentiality obligations no less restrictive than those set forth in this Agreement to the Receiving
Party sufficient to permit the Receiving Party to fulfill its obligations pursuant to this Section 8.

 

		8.3	Non-Use. Each Receiving Party agrees to only use the Confidential Information of the Disclosing
Party to effect the purposes and provisions of this Agreement. For clarity, the provisions of this Section 8 are subject to Sections
2.2 and 7.5.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 10
	 	 	 

    	 

    

 

		8.4	Exceptions. The obligations of a Receiving Party pursuant to Sections 8.2 and 8.3 hereof
shall not apply to the extent the Receiving Party can demonstrate by clear and convincing evidence that the Confidential Information
of the Disclosing Party:

 

		(i)	was in the Receiving Party’s possession prior to the time of disclosure by the Disclosing
Party;

 

		(ii)	is or becomes public knowledge through no fault or omission of the Receiving Party;

 

		(iii)	is obtained by the Receiving Party from a third party under no obligation of confidentiality to
the Disclosing Party; or

 

		(iv)	is required to be disclosed by the Receiving Party in connection with a legal or administrative
proceeding, provided that the Receiving Party shall (A) to the extent permitted by law, give the Disclosing Party prompt
notice of such request and reasonably cooperate with the Disclosing Party to seek an appropriate protective order or other remedy,
and (B) disclose only that portion of such Confidential Information which its legal counsel reasonably determines it is required
to disclose.

 

In addition, the Receiving Party
may disclose Confidential Information of the Disclosing Party that is required to be disclosed by law, by a valid order of a court
or by order or regulation of a governmental agency or stock exchange, or in the course of litigation, provided that to the
extent permitted by law, in all cases the Receiving Party shall give the Disclosing Party prompt notice of the pending disclosure
and make a reasonable effort to obtain, or to assist the Disclosing Party in obtaining a protective order, preventing or limiting
the disclosure and/or requiring that the Confidential Information so disclosed be used only for the purposes for which the law
or regulation required, or for which the order was issued.

 

		8.5	Injunction. Each Party agrees that should it breach or threaten to breach any provisions
of this Section 8, the Disclosing Party will suffer irreparable damages and its remedies at law will be inadequate. Upon any
breach or threatened breach by the Receiving Party of this Section 8, the Disclosing Party shall be entitled to seek injunctive
relief in addition to any other remedy which it may have, without need to post any bond or security.

 

		9	REPRESENTATIONS AND WARRANTIES.

 

		9.1	Mutual Representations and Warranties. Each Party represents and warrants as of the Effective
Date to the other Party as follows:

 

		(i)	it is a corporation duly organized and validly existing under the laws of the state or country
of its incorporation;

 

		(ii)	it has the complete and unrestricted power and right to enter into this Agreement and to perform
its obligations hereunder;

 

		(iii)	this Agreement has been duly authorized, executed and delivered by such Party and constitutes a
legal, valid and binding obligation of such Party enforceable against such Party in accordance with its terms except as enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, receivership, moratorium, fraudulent transfer, or other similar
laws affecting the rights and remedies of creditors generally and by general principles of equity;

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 11
	 	 	 

    	 

    

 

		(iv)	no person or entity has or will have, as a result of the transactions contemplated by this Agreement,
any right, interest or valid claim against or upon such Party for any commission, fee or other compensation as a finder or broker
because of any act by such Party or its agents, or, with respect to Licensee, because of any act by its Affiliates or Sublicensees;

 

		(v)	the execution, delivery and performance of this Agreement does not conflict with any other agreement,
contract, instrument or understanding, oral or written, to which such Party is a party, or by which it is bound, nor will it violate
any law or regulation of any legislature, court, governmental body, administrative agency or other authority (i) in the Territory
for Licensee, or (ii) in the United States of America for HGEN; and

 

		(vi)	as of the Effective Date, for the Licensed Product for the Licensed Indication in the Territory,
(i) it has not received, and none of its Affiliates has received, any notice from any third party claiming that the Licensed Rights
infringes or misappropriates any third party patents or trade secrets or other intellectual property, and (ii) it is not aware
of any infringement or misappropriation by a third party of the Licensed Rights.

 

		9.2	HGEN’s Representations and Warranties. HGEN represents and warrants to Licensee as
follows:

 

		(i)	it owns or controls the Licensed Rights with sufficient rights to grant the license to Licensee
as provided herein described;

 

		(ii)	None of HGEN or any of its Affiliates has granted as of the Effective Date, and HGEN will not,
and shall cause its Affiliates not to grant during the term of this Agreement any right to any third party for the Licensed Product
for the Licensed Indication in the Territory which would conflict with the rights granted to Licensee hereunder.

 

		9.3	Product Warranty. HGEN shall provide to Licensee the benefit of product warranties given
to HGEN by HGEN Contract Manufacturers, effective upon delivery, for all quantities of the Licensed Product supplied by HGEN or
HGEN Contract Manufacturers under this Agreement or the Supply Agreement. Such product warranties shall include at a minimum the
warranties specified in Exhibit K hereto.

 

		9.4	Disclaimer. The warranties set forth in this AGREEMENT
are provided in lieu of, and each party hereby disclaims, all other warranties, express and implied, relating to the subject matter
of this Agreement, THE LICENSED PRODUCT OR the Licensed RIGHTS, including but not limited to the implied warranties of merchantability
and fitness for a particular purpose, title and non-infringement of third party rights. EACH PARTY’s warranties under this
Agreement are solely for the benefit of THE OTHER PARTY and may be asserted only by THE OTHER PARTY and not by any Affiliate, Sublicensee
or customer of THE OTHER PARTY. EACH PARTY shall be solely responsible for all representations and warranties that SUCH PARTY MAKES
TO ANY THIRD PARTY.

 

		9.5	Opportunity to Cure. In the event of a breach of a representation or warranty by a Party,
the other Party shall provide such Party with a reasonable period of time to cure such breach.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 12
	 	 	 

    	 

    

 

		10	INDEMNIFICATION.

 

		10.1	By HGEN. HGEN shall defend, indemnify and hold Licensee and its Affiliates, and each of
their respective directors, officers and employees, harmless from and against any and all losses, damages, liabilities, costs and
expenses (including the reasonable costs and expenses of attorneys and other professionals) (collectively “Losses”)
incurred by Licensee as a result of any claim, demand, action or other proceeding (each, a “Claim”) by a third
party, to the extent such Losses arise out of (i) the negligence or willful misconduct of HGEN or any of its directors, officers
and employees or third party contractors acting on its behalf, or (ii) HGEN’s breach of this Agreement, including without
limitation any of its representations and warranties set forth in Sections 9.1 and 9.2.

 

		10.2	By Licensee. Licensee shall defend, indemnify and hold HGEN and its Affiliates, and each
of their respective directors, officers and employees, harmless from and against any and all Losses incurred by HGEN as a result
of any Claim by a third party, to the extent such Losses arise out of (i) the negligence or willful misconduct of Licensee or any
of its directors, officers and employees or third party contractors acting on its behalf, or (ii) Licensee’s breach of this
Agreement, including without limitation any of its representations and warranties set forth in Section 9.1.

 

		10.3	Procedure. The Party intending to claim indemnification under this Section 10 (an “Indemnitee”)
shall promptly notify the other Party (the “Indemnitor”) of any Claim in respect of which the Indemnitee intends
to claim such indemnification, and the Indemnitor shall assume the defense thereof whether or not such Claim is rightfully brought;
provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid
by the Indemnitee, unless Indemnitor does not assume the defense, and if Indemnitor fails to assume the defense, the reasonable
fees and expenses of counsel retained by the Indemnitee shall be paid by the Indemnitor. The Indemnitee, and its employees and
agents, shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any Claim. The Indemnitor
shall not be liable for the indemnification of any Claim settled or compromised by the Indemnitee without the written consent of
the Indemnitor. As the Parties intend complete indemnification, all costs and expenses of enforcing any provision of this Section 10
shall also be reimbursed by the Indemnitor.

 

		10.4	Insurance. Licensee shall at its cost obtain and maintain the policies of insurance specified
in Exhibit I hereto. Any carrier providing coverage shall have a minimum A.M. Best’s rating of “A-VII”
(or equivalent rating in the Territory). The minimum amounts of insurance coverage required shall not be construed to create a
limit of Licensee’s liability with respect to its indemnification under this Agreement. Licensee shall maintain such insurance
for at least three (3) years from the expiration or termination of this Agreement. Licensee shall provide HGEN with written evidence
of the insurance requirements of this Section 10.4 upon HGEN’s request from time to time.

 

		10.5	[***]

 

		11	LIMITATION OF LIABILITY.

 

		11.1	Limitation of Remedies. Except for damages for which
A PARTY is responsible pursuant to its indemnification obligations set forth in Section 10 above, EACH PARTY specifically
disclaims all liability for and shall in no event be liable for any incidental, special, indirect, consequential, or PUNITIVE damages,
expenses, lost profits, lost savings, interruptions of business or other damages of any kind or character whatsoever arising out
of or related to this Agreement or resulting from the manufacture, handling, marketing, sale, distribution or use of THE LICENSED
Product or use of the Licensed RIGHTS, regardless of the form of action, whether in contract, tort, strict liability or otherwise,
even if A PARTY was advised of the possibility of such damages. NEITHER PARTY shall have ANY remedy, and NEITHER PARTY shall have
liability, other than as expressly set forth in this Agreement.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 13
	 	 	 

    	 

    

 

		11.2	Limitation of Damages. Except with respect to the indemnification specifically provided
in Section 10 above, in no event shall either Party’s total aggregate liability for all claims arising out of or related
to this Agreement exceed the amounts paid by Licensee to HGEN pursuant to Section 4 of this Agreement during the twelve (12) month
period immediately preceding the event giving rise to liability.

 

		11.3	Time for Asserting Damages. No action, regardless of form, arising out of or related to
this Agreement may be brought by either Party more than two (2) years after such Party has knowledge of the occurrence that gave
rise to the cause of such action.

 

		11.4	Liability of KPM and Telcon. Each of KPM and Telcon shall be individually and jointly responsible
and liable for the performance of the obligations of the “Licensee” hereunder. Any breach by KPM of this Agreement
shall be deemed to be the breach of this Agreement by Telcon, and any breach by Telcon of this Agreement shall be deemed to be
the breach of this Agreement by KPM. HGEN may consider KPM and Telcon to be one entity for purposes of this Agreement, and each
of KPM and Telcon shall be deemed to be the agent of the other Party for purposes of notices, waivers, approvals, and other actions
permitted or required under this Agreement.

 

		12	PROPRIETARY RIGHTS.

 

		12.1	Ownership of Proprietary Rights.

 

		(a)	Existing Proprietary Rights. Each Party shall solely own all Proprietary Rights developed
and owned by such Party prior to the Effective Date. For clarity, HGEN shall have sole ownership of the Licensed Patents, the Licensed
Know-How, the Licensed Copyrights, and the Licensed Trademarks.

 

		(b)	Improvements. Notwithstanding Applicable Laws regarding inventorship, HGEN and Licensee
shall jointly own all Proprietary Rights in Improvements. Each Party shall take such actions and execute and deliver such documents
and instruments as may be reasonably requested by the other Party to give effect to the provisions of this Section 12.1(b), and
hereby assigns to the other Party an equal one-half (50%) ownership interest in or with respect to Proprietary Rights in Improvements.
A Party shall provide notice of Improvements to the other Party within sixty (60) days of discovery. All such Proprietary Rights
in Improvements shall be included within the Licensed Rights and may be used by Licensee in accordance with the provisions of this
Agreement applying to Licensed Rights generally. HGEN shall have the non-exclusive, transferable, perpetual, worldwide and royalty-free
right, with the right to grant sublicenses (through multiple tiers of sublicensees), to use jointly-owned Proprietary Rights in
Improvements to make, have made, use, market, distribute, sell, offer for sale, import, export, and otherwise research, develop
and commercialize products formulated with lenzilumab and other products.

 

		12.2	Prosecution and Maintenance. HGEN shall prosecute and maintain, using reasonable discretion,
the Licensed Patents and Licensed Trademarks in the Territory. Licensee shall reimburse HGEN for the reasonable costs of prosecuting
and maintaining the Licensed Patents and Licensed Trademarks in the Territory. HGEN shall have the sole right to control the prosecution
and maintenance of patent applications related to the Licensed Patents and trademark registrations related to the Licensed Trademarks,
provided that HGEN shall provide notice to Licensee of new patent application and trademark registration filings and changes
to the status of patents, patent applications and trademark registrations in the Territory for such prosecution and maintenance
activities.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 14
	 	 	 

    	 

    

 

		12.3	Infringement by Third Parties. If either Party becomes aware that a third party may be infringing
a Licensed Patent or Licensed Trademark in the Territory, it will promptly notify the other Party in writing, providing all information
available to such Party regarding the potential infringement. HGEN shall take whatever, if any, action it deems appropriate to
protect Licensee’ interests in the license granted hereunder against the alleged infringer of the Licensed Patent or Licensed
Trademark. If HGEN elects to take any action, Licensee shall, at HGEN’s request and expense, cooperate and shall cause its
employees to cooperate with HGEN in taking any such action, including but not limited to, cooperating with the prosecution of any
infringement suit by HGEN. The Parties shall equally share all net recoveries after payment or reimbursement of enforcement costs
and expenses. Licensee shall not take any such action against the alleged infringer without the written consent of HGEN.

 

		12.4	Quality Control and Use Provisions for the Licensed Trademarks. Licensee and its Sublicenses
shall additionally comply with the quality control and use provisions specified in Exhibit D for the Licensed Trademarks.

 

		13	TERM AND TERMINATION.

 

		13.1	Term. Subject to the provisions hereunder, the term of this Agreement (the “Term”)
shall commence on the Effective Date and shall continue in effect thereafter, unless terminated earlier as set forth herein, until
the latest to occur of:

 

		(i)	the date which is ten (10) years after the Effective Date;

 

		(ii)	the date on which no regulatory exclusivity applies for the Territory; or

 

		(iii)	the date on which no Licensed Rights cover or would be infringed by the research, development,
manufacture, importation, use, sale, offer for sale, distribution, or other commercialization of the Licensed Product for the Licensed
Indication in the Territory.

 

		13.2	Termination.

 

		(a)	For Cause. If a Party violates or fails to perform any term or covenant of this Agreement,
then the other Party may give written notice of such default (a “Notice of Default”) to such Party. If such
Party fails to cure such default within sixty (60) days (or ten (10) days with respect to any payment obligation) of the effective
date of the Notice of Default, then the other Party may terminate this Agreement by a second written notice (a “Notice
of Termination”) to such Party, and this Agreement shall terminate on the effective date of the Notice of Termination.

 

		(b)	Without Cause by Licensee. Licensee may in its discretion terminate this Agreement, without
cause, upon not less than one hundred eighty (180) days prior written notice to HGEN.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 15
	 	 	 

    	 

    

 

		(c)	Other HGEN Termination Rights. HGEN may in its discretion terminate this Agreement as specified
in Section 6.4(c), Exhibit G and Exhibit H, upon not less than sixty (60) days prior written notice to Licensee.

 

		(d)	For Insolvency. A Party may terminate this Agreement, effective immediately, upon written
notice to the other Party if such other Party becomes insolvent or is adjudicated bankrupt, or a receiver, trustee or custodian
is appointed for it, or there is an assignment of such other Party’s business for the benefit of creditors, or such other
Party liquidates or dissolves, or the occurrence of any action or event equivalent to one or more of the events described in this
Section 13.2(d).

 

		(e)	Termination in the Event of Export Ban. Licensee may terminate this Agreement as specified
in Section 10.5(ii).

 

		13.3	Effect of Termination. Following the termination or expiration of this Agreement, all rights
granted to Licensee herein shall immediately terminate and each Party shall promptly return all relevant records and materials
in its possession or control containing the other Party’s Confidential Information with respect to which the former Party
does not retain rights hereunder; provided, however, that each Party may retain one archival copy of such records and materials
solely to be able to monitor its obligations that survive under this Agreement. At any time following the termination or expiration
of this Agreement, HGEN may, in its sole discretion, request that Licensee assign and transfer all regulatory applications (and
amendments and supplements thereto) and approvals for the Licensed Product for the Licensed Indication in the Territory to HGEN
or its Affiliates or designees. Within thirty (30) calendar days of Licensee’s receipt of HGEN’s request for assignment
and transfer of all regulatory applications and approvals for the Licensed Product for the Licensed Indication in the Territory,
Licensee shall make all necessary and applicable regulatory submissions to the applicable regulatory authority(s) that may be required
to fully effectuate the assignment and transfer of the regulatory applications and approvals to HGEN or its Affiliates or designees
as so designated by HGEN in its request.

 

		13.4	Survival. Notwithstanding any other provisions of this Agreement, any liability or obligation
of either Party to the other for acts or omissions accrued at the time of the termination or expiration of this Agreement shall
survive the termination or expiration of this Agreement. Such termination or expiration shall not relieve either Party from obligations
that are expressly indicated to survive termination or expiration of this Agreement, nor shall any termination or expiration of
this Agreement relieve Licensee of its obligation to pay HGEN royalties for all Licensed Product sold by Licensee, its Affiliates
or Sublicensees, which was accrued at the time of such termination or expiration. The following provisions of this Agreement shall
survive termination or expiration of this Agreement for the periods respectively indicated:

 

	One (1) Year	
        5.1             (Records)

        5.4             (Audit)

	Two (2) Years	
        2.3(b)        (Licensee
        Commitment)

        4.3             (Taxes)

        4.4             (Late
        Payments)

	Five (5) Years	
        7.7             (Publications)

        9.4             (Disclaimer)

        10              (Indemnification)

        13.3           (Effect
        of Termination)

        13.4           (Survival)

        14             (General Provisions)

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 16
	 	 	 

    	 

    

 

	Ten (10) Years	
        2.2             (License
        from Licensee to HGEN)

        7.5             (Access
        to Licensee’s Data)

        (provided, however, that Licensee’s
        obligation to provide a summary of data shall not survive)

        7.6             (Adverse
        Events)

        8                (Confidentiality)

        11             (Limitation
        of Liability)

        12             (Proprietary
        Rights)

 

		14	GENERAL PROVISIONS.

 

		14.1	Relationship of Parties. Each of the Parties hereto is an independent contractor and nothing
in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship
between the Parties. No Party shall incur any debts or make any commitments for the other.

 

		14.2	Third Party Beneficiaries. Except for the rights of Indemnitees pursuant to Section 10 hereof,
the terms and provisions of this Agreement are intended solely for the benefit of each Party hereto and their respective successors
or permitted assigns and it is not the intention of the Parties to confer third-party beneficiary rights upon any other person,
including without limitation Sublicensees.

 

		14.3	Compliance with Law. In connection with the performance of this Agreement, both Parties
shall be in compliance with Applicable Laws. Both Parties agree that their respective use of the Licensed Rights, including without
limitation the manufacture, handling, marketing, sale, distribution and use of the Licensed Product, by each Party, its respective
Affiliates and Sublicensees, as applicable, will comply with Applicable Laws. If applicable, both Parties hereby acknowledge and
agree that all or a portion of the Licensed Rights and/or HGEN’s Confidential Information disclosed hereunder is subject
to, and HGEN shall comply with, export control laws (including without limitation United States Export Controls, under the Export
Administration Regulations, 15 C.F.R. Parts 768-799). In the event that the export, import or delivery of the Licensed Product
is delayed or prohibited under export control laws, HGEN shall promptly notify Licensee of the same and HGEN and Licensee shall
not be liable or responsible for failure or delay in the performance of any of their obligations under this Agreement (including
without limitation Exhibit G and Exhibit H), to the extent HGEN’s or Licensee’s failure or delay to perform is solely
due to the delay or prohibition of the export, import or delivery of the Licensed Product under export control laws.

 

		14.4	Arbitration.

 

		(a)	Negotiations. Any dispute, controversy or claim arising out of or relating to this Agreement
or a breach hereof, including without limitation the validity, construction or effect of this Agreement, or the rights and obligations
created hereunder (a “Dispute”), shall be brought before a conciliation committee of executives representing
both Parties that shall, within thirty (30) calendar days after being informed of the Dispute, attempt to work out a recommendation
for settlement of the Dispute and transmit such recommendation to both Parties for due consideration.

 

		(b)	Arbitration. If after thirty (30) days of consultation the Parties have failed to reach
an amicable settlement of the Dispute, such Dispute shall be submitted to final and binding arbitration at the demand of either
Party upon written notice to that effect to the other Party (a “Demand”). Such Dispute shall be exclusively
and finally resolved by arbitration in accordance with the Rules of Conciliation and Arbitration of the International Chamber of
Commerce (the “ICC”) as then existing. The arbitration proceedings shall be in the English language and shall
be held in Honolulu, Hawaii, USA.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 17
	 	 	 

    	 

    

 

		(c)	Arbitral Panel. The arbitral panel shall consist of one (1) arbitrator acceptable to Licensee
and HGEN. If Licensee and HGEN cannot agree on a single arbitrator within thirty (30) days after a Demand has been made, Licensee
shall appoint an arbitrator, HGEN shall appoint an arbitrator, the two (2) arbitrators shall appoint a third arbitrator, and the
three (3) arbitrators shall hear and decide the Dispute. If either Party fails to appoint an arbitrator within forty five (45)
days after service of the Demand for arbitration, then the ICC shall appoint an arbitrator for such Party.

 

		(d)	Arbitral Awards. The arbitral award shall be in writing in English, shall not be contrary
to the governing law of this Agreement, shall not award damages excluded by Section 11, shall provide reasons for the award, and
shall be final and binding upon the Parties hereto. The losing Party shall pay all reasonable out-of-pocket expenses (including,
without limitation, reasonable attorneys’ fees) incurred by the prevailing Party, as determined by the arbitrators, in connection
with any Dispute unless the arbitrators direct otherwise. Each Party waives any right it may have by statute, treaty or law to
contest the jurisdiction or venue of any court or service made pursuant to Section 14.7 hereof in an action or proceeding to enforce
an arbitral award, and each Party agrees that the validity of arbitral awards shall only be challenged in accordance with Article
V of the United Nations Convention on the Recognition and Enforcement of Foreign Arbitral Awards.

 

		(e)	Interim Remedies. The Parties recognize and acknowledge that a breach by one Party of any
of its covenants, agreements, obligations or undertakings hereunder with respect to security, confidentiality, assignment and transfer
of regulatory applications and approvals following termination, or compliance with Applicable Laws may cause the non-breaching
Party irreparable damage, which cannot be readily remedied by monetary damages in an action at law. In the event of any such breach,
the non-breaching Party shall be entitled, in addition to all remedies accorded by law, to equitable relief (including but not
limited to injunctive relief) in any court having jurisdiction to protect its interests pending arbitration as provided in this
Section 14.4.

 

		(f)	Confidentiality of Proceedings. All arbitration proceedings hereunder shall be confidential,
and the arbitrator(s) shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except
as permitted by Section 8.4 above, neither Party shall make (or instruct the arbitrator(s) to make) any public announcement with
respect to the proceedings or decision of the arbitrator(s) without prior written consent of the other Party.

 

		(g)	Binding Effect. The provisions of this Section 14.4 shall survive any expiration or termination
of this Agreement, and shall be severable and binding on the Parties hereto, notwithstanding that any other provision of this Agreement
may be held or declared to be invalid, illegal, or unenforceable.

 

		14.5	Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of New York (without giving effect to any conflicts of law principles that require the application of the law
of a different state or nation).

 

		14.6	Costs and Expenses. Except as otherwise expressly provided in this Agreement, each Party
shall respectively bear all costs and expenses associated with the performance of such Party’s obligations under this Agreement.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 18
	 	 	 

    	 

    

 

		14.7	Notices. Any notice, request, or communication under this Agreement shall be effective only
if it is in writing and (i) personally delivered, or (ii) sent by internationally recognized overnight courier with signature required,
addressed to the Parties at the addresses stated below or such other persons and/or addresses as shall be furnished in writing
by the respective Party in accordance with this Section 14.7. Unless otherwise provided, all notices shall be sent:

 

	
        If to Licensee:

         

        KPM Tech Co.,
        Ltd.

        122, Sandan-ro
        163beon-gil

        Danwon-gu

        15429

        South Korea

        Attention:
        Chief Executive Officer

        Telephone:
        +82-2-567-8002

         
	
        If to HGEN:

         

        Humanigen, Inc.

        533 Airport
        Blvd Ste 400

        Burlingame,
        CA 94010, USA

        Attention: Chief Executive Officer

        Telephone:
        +1-650-243-3100

	
        With a copy to:

         

        Telcon RF Pharmaceutical,
        Inc.

        54, Gongse-ro,
        Giheung-gu,

        17086

        South Korea

        Attention:
        Chief Executive Officer

        Telephone:
        +82-2-515-8808

         
	
        With copies to:

         

        Humanigen, Inc.

        533 Airport
        Blvd Ste 400

        Burlingame,
        CA 94010, USA

        Attention: Chief Financial Officer

        Telephone: +1-650-243-3100

         

	
        With copies via email to:

         

        kpm.kang@kpmtech.co.kr
	
        With copies via email to:

         

        BAtwill@Humanigen.com

        RPratt@LifeScienceLegal.com

         

 

If personally delivered, the
date of delivery shall be deemed to be the date on which such notice, request or communication was given. If sent by overnight
courier, the third business day after the date of deposit with such courier shall be deemed to be the date on which such notice,
request or communication was given.

 

		14.8	Public Announcements. Except for such disclosure as is deemed necessary, in the reasonable
judgment of a Party, to comply with applicable laws or regulations, securities filings or the rules of a stock exchange, no announcement,
news release, public statement, publication, or presentation relating to the existence of this Agreement, or the terms hereof,
will be made without the other Party’s prior written approval, which approval shall not be unreasonably withheld. Notwithstanding
the above, the Parties hereby agree to the content of and authorize public announcements made after the Effective Date generally
with the content set forth in Exhibit J hereto. HGEN shall be free to disclose to third parties the fact that it has entered
into this Agreement with Licensee (including a description of the Licensed Indication, the Territory, and the Licensed Product),
as well as any other information contained in Exhibit J hereto.

 

		14.9	Entire Agreement; Amendment. This Agreement and all Exhibits attached hereto, together with
the Supply Agreement, the Quality Agreement, the PV Agreement and the Services Agreement, contain the entire agreement of the Parties
relating to the subject matter hereof and supersede any and all prior agreements, written or oral, between HGEN and Licensee relating
to the subject matter hereof. This Agreement may not be amended unless agreed to in writing by both Parties.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 19
	 	 	 

    	 

    

 

		14.10	Binding Effect. This Agreement shall be binding upon and inure to the benefit of, and the
rights and obligations hereof shall apply to, HGEN and Licensee and any successor(s) and permitted assigns. The name of a Party
appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary
to carry out the intent of this Agreement.

 

		14.11	Waiver. The rights of either Party under this Agreement may be exercised from time to time,
singularly or in combination, and the exercise of one or more such rights shall not be deemed to be a waiver of any one or more
of the others. No waiver of any breach of a term, provision or condition of this Agreement shall be deemed to have been made by
either Party unless such waiver is addressed in writing and signed by an authorized representative of that Party. The failure of
either Party to insist upon the strict performance of any of the terms, provisions or conditions of this Agreement, or to exercise
any option contained in this Agreement, shall not be construed as a waiver or relinquishment for the future of any such term, provision,
condition or option or the waiver or relinquishment of any other term, provision, condition or option.

 

		14.12	Severability. If a final arbitral or judicial determination is made that any provision of
this Agreement is unenforceable, such provision shall be rendered void only to the extent that such determination finds such provision
unenforceable, and such unenforceable provision shall be automatically reconstituted and become a part of this Agreement, effective
as of the Effective Date, to the maximum extent they are lawfully enforceable.

 

		14.13	Assignment. Licensee shall not assign its rights or delegate its obligations under this
Agreement, in whole or in part, by operation of law or otherwise, to any third party without the prior written consent of HGEN,
which shall not be unreasonably withheld or delayed. HGEN may assign its rights and delegate its obligations under this Agreement
(without modification of the terms of this Agreement) to an Affiliate or to a third party successor that acquires all or substantially
all of its business or assets to which this Agreement relates (whether by way of merger, reorganization, acquisition, sale, sale
of stock, operation of law or otherwise) without the other Party’s prior written consent; provided that the terms
and conditions of this Agreement are not changed or modified without prior written consent and agreement of Licensee. As a condition
to any permitted assignment hereunder, the assignor must guarantee the performance of any assignee to the terms and obligations
of this Agreement and in the event that the assignor is HGEN, it shall provide to Licensee a written agreement that such assignee
shall be bound by the provisions of this Agreement. Any assignment not in accordance with this Section 14.13 shall be null
and void.

 

		14.14	Headings. The descriptive headings of this Agreement are for convenience only, and shall
be of no force or effect in construing or interpreting any of the provisions of this Agreement.

 

		14.15	Execution. This Agreement may be executed in multiple counterparts, each of which shall
constitute an original document, but all of which shall constitute one and the same instrument. Signatures to this Agreement transmitted
by facsimile, by email in “portable document format” (“.pdf”) or by any other electronic means intended
to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as physical delivery of
the paper document bearing original signature.

 

		14.16	Individual or Collective Exercise and Enforcement. Any and all rights and remedies granted
to the Licensee hereunder may be exercised and enforced by KPM or Telcon, individually or collectively, at the sole discretion
of the Licensee.

 

[Remainder of this page left blank intentionally]

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 20
	 	 	 

    	 

    

 

IN WITNESS WHEREOF,
the Parties have executed this Agreement as of the Effective Date.

 

 

HUMANIGEN, INC.

 

 

 

	By:	/s/ Cameron Durrant	 
	 	 	 
	Name:	Cameron Durrant	 
	 	 	 
	Title:	Chairman & CEO	 
	 	 	 
	 	 	 
	KPM TECH CO., LTD.	 
	 	 	 
	 	 	 
	 	 	 
	By:	/s/ Kim Ji Hoon	 
	 	 	 
	Name:	Kim Ji Hoon	 
	 	 	 
	Title:	President	 
	 	 	 
	 	 	 
	TELCON RF PHARMACEUTICAL, INC.	 
	 	 	 
	 	 	 
	 	 	 
	By:	/s/ Kim Ji Hoon	 
	 	 	 
	Name:	Kim Ji Hoon	 
	 	 	 
	Title:	CEO	 

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	PAGE 21
	 	 	 

    	 

    

 

EXHIBIT A: DEFINITIONS

 

For the purposes of
this Agreement, the following terms shall have meanings as defined below:

 

“Affiliate”
means, with respect to any Party, any entity directly, or indirectly through one or more intermediaries, controlling, controlled
by, or under common control with such party, during and for such time as such control exists. For these purposes, “control”
shall mean:

 

		(i)	for HGEN, the ownership, directly or indirectly, of at least fifty percent (50%) of the voting
securities or other ownership interest of the relevant entity; or

 

		(ii)	for Licensee, that a party is the largest shareholder or possesses the power to elect members of
the board of directors of the relevant entity.

 

“Applicable
Laws” means all applicable international, national, federal, state, and local laws, rules and regulations. With respect
to HGEN’s performance under this Agreement, Applicable Laws shall solely refer to the laws of the United States of America.
With respect to Licensee’s performance under this Agreement, Applicable Laws shall refer to the laws of the Territory and
to any of the laws of the United States of America applicable to Licensee’s importation, development, testing, commercialization,
or sale of the Licensed Product for the Licensed Indication in the Territory.

 

“Claim”
has the meaning specified in Section 10.1.

 

“Confidential
Information” has the meaning specified in Section 8.1.

 

“Demand”
has the meaning specified in Section 14.4(b).

 

“Development
Plan” has the meaning specified in Section 6.2(a).

 

“Disclosing
Party” has the meaning specified in Section 8.1.

 

“Dispute”
has the meaning specified in Section 14.4(a).

 

“HGEN Contract
Manufacturer” has the meaning specified in Section 3.2(b).

 

“ICC”
has the meaning specified in Section 14.4(b).

 

“Improvement”
means any improvement, new invention, discovery, idea, technique and other technology, whether or not patentable, related to the
Licensed Product, that is developed by Licensee or its Affiliates or Sublicensees from and after the Effective Date, either (i)
solely or (ii) jointly with a third party and/or HGEN, its Affiliates or their permitted licensees.

 

“Indemnitee”
has the meaning specified in Section 10.3.

 

“Indemnitor”
has the meaning specified in Section 10.3.

 

“Licensed
Copyrights” means the copyrights described in Exhibit C hereto.

 

“Licensed
Indication” means COVID-19 pneumonia, or a clinically-equivalent indication, which might be narrower but not broader,
that is approved by the applicable regulatory authority in the Territory.

 

“Licensed
Know-How” means the know-how described in Exhibit C hereto.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT A-1
	 	 	 

    	 

    

 

“Licensed
Patents” means all patents which would be infringed (if not licensed to Licensee pursuant to this Agreement), either
directly or indirectly, by Licensee’s research, development, manufacture, importation, use, sale, offer for sale, distribution
or other commercialization of the Licensed Product for the Licensed Indication in the Territory and which are either as of the
Effective Date or at any time during the Term (i) owned by HGEN or any HGEN Affiliate, or (ii) licensed to HGEN or any HGEN Affiliate
by a third party with the right to sublicense, including in each case any and all extensions, renewals, continuations, substitutions,
continuations-in-part, divisions, patents-of-addition, reissues, reexaminations and/or supplementary protection certificates to
any such patents. Set forth in Exhibit B attached hereto is a list of the Licensed Patents as of the Effective Date.
Such Exhibit B may be updated by HGEN from time to time during the Term.

 

“Licensed
Product” has the meaning specified in Exhibit E hereto.

 

“Licensed
Rights” means the Licensed Patents, the Licensed Know-How, the Licensed Copyrights, and the Licensed Trademarks.

 

“Licensed
Trademarks” means the trademarks described in Exhibit D hereto.

 

“Losses”
has the meaning specified in Section 10.1.

 

“Net Sales”
has the meaning specific in Exhibit F hereto.

 

“Notice of
Default” has the meaning specified in Section 13.2.

 

“Notice of
Termination” has the meaning specified in Section 13.2.

 

“Proprietary
Rights” means all inventions, products, processes, methods, techniques, formulas, compositions, compounds, projects,
developments, plans, research data, market data, clinical data, financial data, personnel data and computer programs; all client,
customer, account and supplier lists and files; all files, letters, memoranda, reports, data, sketches, drawings, laboratory notebooks,
program listings and other written, photographic and tangible materials; all improvements, discoveries, enhancements, software
and works of authorship; and all patent, copyright, mask works, trademark, trade name and other intellectual or proprietary property
rights related to any of the foregoing.

 

“PV Agreement”
means that certain Pharmacovigilance and Safety Data Exchange Agreement entered into between HGEN and Licensee prior to the earlier
of (i) any use of the Licensed Product in humans (including without limitation for clinical trials) for the Licensed Indication
in the Territory, or (ii) the date which is one hundred twenty (120) days after the date of the approval of a BLA for the Licensed
Product in the U.S.

 

“Quality Agreement”
means that certain Quality Agreement entered into between HGEN and Licensee prior to the earlier of (i) any use of the Licensed
Product in humans (including without limitation for clinical trials) for the Licensed Indication in the Territory, or (ii) the
date which is one hundred twenty (120) days after the date of the approval of a BLA for the Licensed Product in the U.S. for the
supply of the Licensed Product. For clarity orders for the Licensed Product under the Supply Agreement will not be accepted without
a Quality Agreement in place.

 

“Receiving
Party” has the meaning specified in Section 8.1.

 

“Services
Agreement” means that certain Services Agreement entered into between HGEN and Licensee prior to the earlier of (i) any
use of the Licensed Product in humans (including without limitation for clinical trials) for the Licensed Indication in the Territory,
or (ii) the date which is one hundred twenty (120) days after the approval of a BLA for the Licensed Product in the U.S. for services
provided by HGEN related to the Licensed Product. No services included in or outside of this agreement will be provided by HGEN
without an executed Services Agreement.

 

“Sublicensees”
has the meaning specified in Section 2.1(d).

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT A-2
	 	 	 

    	 

    

 

“Supply Agreement”
means that certain Supply Agreement entered into between HGEN and Licensee prior to the earlier of (i) any use of the Licensed
Product in humans (including without limitation for clinical trials) for the Licensed Indication in the Territory, or (ii) the
date which is one hundred twenty (120) days after the approval of a BLA for the Licensed Product in the U.S., for the supply of
the Licensed Product, which shall incorporate the key terms and conditions specified in Exhibit K hereto.

 

“Term”
has the meaning specified in Section 13.1.

 

“Territory”
means the following countries: (i) South Korea (Republic of Korea) and (ii) the Philippines (Republic of the Philippines).

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT A-3
	 	 	 

    	 

    

 

EXHIBIT B: LICENSED PATENTS

 

As used in this Agreement,
the “Licensed Patents” shall include without limitation the following patents and patent applications:

 

A.       Patents
owned by HGEN or an Affiliate(s).

 

	METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING 

INFLAMMATION-INDUCED LUNG INJURY
         

	
	Country	Status	Expiry Date (Estimated)
	United States 	 	 
	U.S. Provisional App. No.: 62/986,751 March 2020	Pending	N/A
	
        U.S. Provisional App. No.: 63/027,128

        May 2020
	Pending	N/A
	
        U.S. Provisional App. No.: 63/072,716

        August 2020
	Pending	N/A
	
        U.S. Provisional App. No.: 63/088,971

        October 2020
	Pending	N/A
	
        PCT International Application

        The South Korean and Philippine

        applications will be via national phase

        entry of the PCT in these countries.
	
        To be filed

        March 2021
	March 2041

 

	
        ANTIBODIES TO GRANULOCYTE-MACROPHAGE
        

        COLONY-STIMULATING FACTOR

         

	Country	Status	Expiry Date (Estimated)
	United States 	 	 
	US Patent No. 8,168,183	Registered	28-Apr-29
	US Patent No. 9,017,674	Registered	28-Apr-29 
	South Korea	 	 
	Patent No. 10-1824512	Registered	28-Apr-29
	Patent No. 10-1852915	Registered	28-Apr-29
	Philippines	 	 
	None	Not Applicable	Not Applicable

 

B.       Patents
licensed by HGEN or an Affiliate(s) from a third party.

 

None.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT B-1
	 	 	 

    	 

    

 

EXHIBIT C: LICENSED KNOW-HOW AND LICENSED
COPYRIGHTS

 

As used in this Agreement,
“Licensed Know-How” shall mean the following information to the extent owned or controlled (with the right to
license to Licensee) by HGEN or its Affiliates and reasonably relating to the research, development, manufacture, or commercialization
of the Licensed Product for the Licensed Indication in the Territory:

 

		1.	[***]

 

		2.	[***]

 

		3.	[***]

 

		4.	[***]

 

		5.	[***]

 

		6.	[***]

 

		7.	[***]

 

		8.	[***]

 

		9.	[***]

 

		10.	[***]

 

		11.	[***]

 

		12.	[***]

 

		13.	[***]

 

		14.	[***]

 

As used in this Agreement,
“Licensed Copyrights” shall mean rights of copyright in the following items:

 

		1.	Protocols.

 

		2.	Investigator brochure.

 

		3.	Labeling, packaging and package insert text, design, images, and logos.

 

		4.	Fact sheets.

 

		5.	Web site content.

 

		6.	Regulatory information and filings.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT C-1
	 	 	 

    	 

    

 

EXHIBIT D: LICENSED TRADEMARKS

 

		A.	Specification of the Licensed Trademarks. Subject to regulatory requirements in each applicable
country within the Territory, Licensee and its Sublicensees shall display one (1) of the following trademarks (as determined by
HGEN in its reasonable discretion) on the packaging and promotional materials for the Licensed Product:

 

		1.	LENZILUMAB TM; or

 

		2.	Some other trademark chosen by HGEN from time to time, which shall be reasonably acceptable to
Licensee.

 

		B.	Quality Control and Use Provisions for the Licensed Trademarks. Licensee and its Sublicensees
shall comply with the following quality control and use requirements related to the Licensed Trademarks:

 

		1.	The Licensed Trademarks must be reasonably visible, but at Licensee’s sole discretion may
be smaller than Licensee’s own branding and trademarks.

 

		2.	The Licensed Trademarks may only be used in connection with the Licensed Product for the Licensed
Indication, provided that Licensed Product shall meet the specifications approved by the relevant regulatory authority.

 

		3.	The Licensed Trademarks shall be used in such form and manner as may be approved by HGEN, including
use of ® or TM as appropriate.

 

		4.	The Licensed Trademarks shall not be used as a trade name or as part of a corporate name.

 

		5.	An appropriate notice shall be included on all materials and electronic communications that use
the Licensed Trademarks, indicating that the Licensed Trademarks are registered and/or owned by HGEN.

 

		6.	HGEN shall have the right to impose, and Licensee and its Sublicensees shall comply with, reasonable
quality standards for the use and display of the Licensed Trademarks.

 

		C.	Goodwill. The Licensed Trademarks, including without limitation all right, title and interest
therein, all goodwill related thereto and the right to registrations thereof in all countries are and shall remain the sole and
exclusive property of HGEN. Use of the Licensed Trademarks by Licensee and its Sublicensees, and any goodwill arising therefrom,
shall inure to the sole benefit of HGEN and any enhancement in the value of the Licensed Trademarks that results from such use
shall be effected to the sole benefit of HGEN and shall not give rise to any compensation to Licensee in the event of the termination
of the Agreement.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT D-1
	 	 	 

    	 

    

 

EXHIBIT
E: LICENSED PRODUCT 

 

“Licensed Product” shall
mean lenzilumab (10mg/ml filled into a 10ml vial).

 

(As of the Effective Date, the standard
dosage for patients for the Licensed Indication is 600mg via IV infusion every 8 hours for a total of 3 doses.)

 

The specifications for the Licensed Product
(clinical trial material specifications) are as follows:

 

	Test	Method	Acceptance Criteria
	
         

        [***]
	
         

        [***]
	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	
         

        [***]
	
         

        [***]
	
        • [***]

        • [***]

        • [***]

	
         

        [***]
	
         

        [***]
	[***]

[***]
	
         

         

        [***]
	
         

         

        [***]
	
        • [***]

        • [***]

	
         

        [***]
	
         

        [***]
	[***]
	[***]	[***]	[***]
	[***]	[***]	[***]
	
         

        [***]
	
         

        [***]
	
        • [***].

        • [***]

a [***] and
[***] performed
at release
only.

 

The above specifications for the Licensed
Product are currently filed with the FDA in the IND and apply to the clinical trial materials being used as of the Effective Date.
Updated specifications are under development to support EUA and BLA filings. HGEN shall have the right to modify, and as of the
Effective Date is in the process of modifying, the above specifications.

 

For clarity, the Licensed Product shall
not include any product which is a combination or sequenced product where lenzilumab is used alongside or in combination with any
other active ingredient or pharmaceutical product.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT E-1
	 	 	 

    	 

    

 

EXHIBIT F: COMPENSATION FOR LICENSE

 

		A.	Signature Payment. Licensee shall pay to HGEN a non-refundable, one-time fee of Six Million
Dollars (US$6,000,000) in consideration for work performed by HGEN prior to the Effective Date to develop the Licensed Product,
which amount shall be due and payable in full within five (5) calendar days after receipt of an invoice from HGEN after the Effective
Date.

 

		B.	Milestone Payments. Within ten (10) business days following written notice from HGEN to
License of the occurrence of each of the milestone events listed below with respect to the Licensed Product, Licensee shall pay
to HGEN the applicable non-refundable milestone fee listed next to each such event in further consideration of the rights granted
Licensee hereunder. The milestone payments are as follows:

 

	Milestone	Milestone Payment
	Last patient dosed in the US Phase 3 clinical trial in progress as of the 

Effective Date and top line “Successful” results of such US Phase 3 

clinical trial announced to the US stock market	US$6,000,000
	
        After completion of a US Phase 3 clinical trial, the issuance
        of any

        regulatory authorization or approval permitting the sale of the Licensed

        Product in the USA, including without limitation any of the following:

        (i)         an Emergency Use
        Authorization;

        (ii)        an approved Biologics
        License Application; or

        (iii)       an approved New
        Drug Application.

	US$8,000,000

 

Each milestone payment specified
above shall only be payable one time.

 

As used in this Agreement, “Successful”
means a statistically significant result on the primary endpoint or any of the key secondary endpoints either in the modified intent
to treat analysis (mITT) or the per-protocol analysis (PP).

 

		C.	Royalties. In addition to amounts payable pursuant to Sections A and B above, Licensee
shall make royalty payments to HGEN during the Term on a calendar quarterly basis, in an amount equal to [***] percent ([***]%)
of Net Sales for the relevant period of time. All royalties payable to HGEN pursuant to this Section C shall be due and payable
within forty five (45) days after the conclusion of each calendar quarter.

 

As used in this Agreement, “Net
Sales” means, with respect to a given period of time, gross sales of the Licensed Product by KPM or Telcon from the first
sale at arm’s length to a third party in such period, less the following deductions which are actually incurred, allowed,
paid, accrued or specifically allocated to such gross sales amounts of Licensed Product:

 

		(i)	credits or allowances actually granted for damaged Licensed Product, returns or rejections of Licensed
Product, price adjustments and billing errors;

 

		(ii)	normal and customary trade, cash and quantity discounts, allowances, and credits;

 

		(iii)	storage costs and transportation costs paid to third parties, including insurance, for outbound
freight related to delivery of Licensed Product to the extent included in the gross amount invoiced; and

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT F-1
	 	 	 

    	 

    

 

		(vi)	sales taxes, value added taxes and other taxes applied to the sale of Licensed Product to the extent
included in the gross amount invoiced.

 

A Licensed Product shall be considered
sold when it is shipped, delivered or invoiced, whichever is earlier. No deductions shall be made for commissions paid to individuals
or companies or for the cost of collections. If Licensed Product is sold or transferred (i) for consideration, in whole or in part,
other than cash, or (ii) at a discounted price for purposes of promoting the sale of other goods or services, then the Net Sale
price for such Licensed Product shall be deemed to be the average invoice price then being invoiced by Licensee for cash sales
in the relevant calendar quarter for the Licensed Product alone. Net Sales shall be calculated in the ordinary course of business
using the accrual method of accounting in accordance with International Financial Reporting Standards. Sales of Licensed Product
between or among Licensee and its Affiliates or Sublicensees shall be excluded from the computation of Net Sales, but the subsequent
final sales of the Licensed Product to third parties by such Affiliates or Sublicensees shall be included in the computation of
Net Sales.

 

		D.	Share of Sublicensee Payments. In addition to amounts payable pursuant to Sections A,
B and C above, Licensee shall make payments to HGEN during the Term on a calendar quarterly basis in an amount equal to [***] percent
([***]%) of any fee or payment received from Sublicensees during such quarter (collectively “Sublicense Fees”).
Sublicense Fees shall include without limitation any signing or “up front” payment, “milestone” payment,
fixed fee, royalty payment, unearned portion of any minimum royalty payment, equity, joint marketing fees, intellectual property
fees, research, development or commercialization funding in excess of Licensee’s cost of performing the relevant activities,
and any other property, consideration or thing of value given or exchanged for a sublicense regardless of how the Licensee and
Sublicensee characterize such payments or consideration. For clarity, Sublicense Fees shall not include the purchase price for
Licensed Product for sales of Licensed Product between or among Licensee and its Affiliates or Sublicensees, provided that
revenues from the resale of the Licensed Products by such Affiliates and Sublicenses is included in the calculation of Net Sales.

 

		E.	Allocation of Payments. Payments to be made by Licensee to HGEN pursuant to this Exhibit
F shall be allocated and paid as follows: (i) fifty percent (50%) by KPM, and (ii) fifty percent (50%) by Telcon.

 

		F.	Acknowledgement. In establishing the compensation structure hereunder, the Parties recognize,
and Licensee acknowledges, the substantial value of the various obligations being undertaken by HGEN under this Agreement, in addition
to the grant of the license under the Licensed Rights, to enable the rapid and effective market introduction of the Licensed Product
for the Licensed Indication in the Territory. The Parties have agreed to the payment structure set forth herein as a convenient
and fair mechanism to compensate HGEN for these obligations.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT F-2
	 	 	 

    	 

    

 

EXHIBIT G: RETENTION OF EXCLUSIVITY
REQUIREMENTS

 

Pursuant and subject
to Sections 2.1(b) and 6.4(b) of the Agreement, the license provided under Section 2.1(a)(ii) of the Agreement shall be exclusive,
for the Territory, for so long as Licensee is in compliance with the relevant requirements specified in the following table:

 

	Minimum Number of Units Sold in the Territory
	2020	2021	2022	2023	2024	2025	Each Year 

Thereafter
	None	[***]	[***]	[***]	[***]	[***]	[***]

 

If Licensee at any time is not in compliance
with any of the foregoing exclusivity requirements, then for each calendar year HGEN may elect to enforce one of the following
remedies, to be exercised not later than the date which is sixty (60) days after the date Licensee has provided all required quarterly
and annual reports pursuant to Sections 5.2 and 5.3 for the relevant calendar year:

 

		1.	By notice from HGEN to Licensee of not less than sixty (60) days, the rights of Licensee for the
Territory shall thereafter be non-exclusive pursuant to Section 2.1(b)(ii) for all subsequent calendar years.

 

		2.	By notice from HGEN to Licensee of not less than sixty (60) days, HGEN shall have the right to
terminate this Agreement pursuant to Section 6.4(c).

 

		3.	Upon presentation of an invoice by HGEN to Licensee, Licensee shall pay HGEN an amount equal to
[***] percent ([***]%) of Net Sales that would have been earned from the sale of shortfall quantities (the difference between the
number of units specified above to be sold and the number of units actually sold) in the relevant calendar year.

 

Provided, however, that (i) HGEN
may initially elect to enforce subparagraph (3) above only, but (ii) upon Licensee’s refusal and/or failure to pay the full
amount required to be paid to HGEN under such subparagraph (3) within thirty (30) days from receipt by Licensee of HGEN’s
notice of election to enforce subparagraph (3) above, HGEN may, at its option, enforce either subparagraph (1) or subparagraph
(2) above for that year and all subsequent years.

 

The specific “Minimum Number of Units”
may be adjusted and changed (decreased or increased), when commercialization plans and launch plans are agreed, through mutual
discussion between HGEN and Licensee, provided that adjustments or changes are in the discretion of each Party and must
be in the form of an amendment to this Agreement.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT G-1
	 	 	 

    	 

    

 

EXHIBIT H: SPECIFIC DILIGENCE REQUIREMENTS

 

Pursuant to Section
6.4(c) of the Agreement, HGEN may terminate the Agreement pursuant to Section 13.2 if Licensee does not comply with any of the
following requirements:

 

		1.	Competing Products. Licensee and its Affiliates and Sublicensees shall not sell a product
other than the Licensed Product which (i) contains lenzilumab, (ii) uses the same mechanism of action (for example, other anti-GM-CSF
mAbs), or (iii) is indicated for the Licensed Indication. The Parties shall consult to clarify what is or is not a competing product
if requested by either Party.

 

		2.	Corporate Support. Licensee shall devote and expend sufficient resources to implement the
then-current Development Plan, Launch Plan and Commercialization Plan.

 

		3.	Deadline to File for Regulatory Approval. Upon execution of this Agreement, Licensee shall
make its commercially reasonable efforts to file for regulatory approvals in the Territory within four (4) months after the issuance
of a BLA permitting the sale of the Licensed Product in the USA.

 

		4.	Marketing Approval. Licensee or its Sublicensee shall make its commercially reasonable efforts
to obtain marketing approval for the Licensed Product for the Licensed Indication in the Territory within six (6) months after
issuance of any of the following in the USA:

 

		(i)	an approved Biologics License Application; or

 

		(ii)	an approved New Drug Application.

 

If the Ministry
of Food and Drug Safety (“MFDS”) in South Korea does not permit Licensee to obtain the marketing approval of
the Licensed Product within this six (6) month period in South Korea due to the delay of MFDS or technical issues causing delay
of related clinical trials in South Korea, then HGEN agrees that this provision will be exceptionally applied in this Agreement
so that the six (6) month period is extended by the period of delay which is not due to the late filing for regulatory approval
by Licensee or other fault or delay of Licensee.

 

		5.	Launch. Licensee or its Sublicensee shall commence commercial sale of the Licensed Product
for the Licensed Indication in the Territory within sixty (60) days after marketing approval.

 

		6.	Sales. The Licensed Product shall be generally available for sale in the Territory for the
Licensed Indication, after marketing approval (any period of non-availability shall not exceed twelve (12) months).

 

		7.	Promotion. The Licensed Product shall be actively and continuously promoted for the Licensed
Indication, after marketing approval in the Territory. For purposes of this Section 7, Licensee or its Sublicensee shall be deemed
to have not actively and continuously promoted the Licensed Product if less than:

 

		(i)	US$[***] has been spent in the first (12) months after marketing approval in the Territory for
such promotion; or

 

		(ii)	a mutually agreed amount as specified in the then-current commercialization plan has been spent
in any other continuous period of twelve (12) months for such promotion.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT H-1
	 	 	 

    	 

    

 

EXHIBIT I: INSURANCE REQUIREMENTS

 

Licensee
shall obtain and maintain the following policies of insurance:

 

		1.	General Liability. Commercial general liability insurance, including broad form contractual
liability insurance, covering bodily injury and property damage for Licensee’s indemnification under this Agreement, in amounts
not less than US$1,000,000 per incident and US$2,000,000 in the aggregate.

 

		2.	Clinical Trial Liability. At such time as any Licensed Product is being tested in a clinical
trial in the Territory, Licensee shall at its sole cost and expense, procure and maintain clinical trial liability insurance with
limits not less than US$ 10,000,000 per occurrence and in the aggregate. For clarity, in no event shall the Licensed Product be
tested in a clinical trial or any other study in the Territory for any use other than the Licensed Indication.

 

		3.	Products Liability. At such time as any Licensed Product is being commercially distributed
or sold by Licensee or a Sublicensee, Licensee shall at its sole cost and expense, procure and maintain products liability insurance
in amounts not less than US$10,000,000 per incident and in the aggregate.

 

		4.	Workers Compensation. Insurance for the protection of Licensee employees from injury or
death as legally required in the Territory.

 

All such policies shall name HGEN as an
additional insured and shall be on a “claims incurred” (not “claims made”) basis.

 

Such insurance will be considered primary
as to any other valid and collectible insurance, but only as to acts of the named insured.

 

[***]

 

For clarity, the policies limits of insurance
specified in this Exhibit I or as obtained from time to time by Licensee shall not be deemed to limit the rights or maximum
liability of Licensee. The rights of a Party to the proceeds of insurance shall be without prejudice to any rights or remedies
such Party may have under this Agreement or otherwise at law generally, provided that neither Party shall be entitled to
double recoveries or recoveries in excess of actual direct damages properly established by such Party.

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT I-1
	 	 	 

    	 

    

 

EXHIBIT J: CONTENT FOR PUBLIC ANNOUNCEMENTS

 

 

 

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT J-1
	 	 	 

    	 

    

 

Humanigen
Executes Licensing Agreement for LenzilumabTM in
COVID-19 with KPM Tech/Telcon RF Pharmaceutical 

for South Korea and the
Philippines 

 

		·	Agreement provides
Humanigen up to US$20 million in milestones

		·	Transaction supports
the Humanigen Asia-Pacific regional corporate development strategy 

 

Burlingame, CA, November 3, 2020 –
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical
company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate
lenzilumab, today announced the execution of its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical,
Inc. (“Telcon”) (200230.KQ) and KPM Tech Co., Ltd (“KPM Tech”) (042040.KQ) for development and commercialization
rights to lenzilumab for COVID-19 for South Korea and the Philippines.

 

Telcon is an affiliate of KPM Tech and
both companies recently invested in the Humanigen June 2020 PIPE offering. Telcon produces liquid formulations, tablets, pills,
capsules, and other pharmaceutical products, as well as communication equipment.

 

Mr. Ji-Hoon Kim, CEO of Telcon and KPM
Tech, said, “We have supported Humanigen through an equity investment and see lenzilumab as an excellent therapeutic solution
for the hyperinflammation seen in COVID-19 hospitalized patients. Lenzilumab has a significant part to play in the treatment of
patients in the pandemic and beyond. We are honored to be selected to develop and potentially launch lenzilumab in South Korea
and the Philippines.”

 

The licensing agreement includes payments
of up to US$20 million with US$6 million as an upfront payment upon execution of the licensing agreement and the balance of US$14
million in two payments based on achievement by Humanigen of specified milestones in the US. Telcon and KPM Tech will be responsible
for gaining regulatory approval and subsequent commercialization of lenzilumab in its territories. Humanigen will earn double-digit
royalties following receipt of those approvals on net sales subsequent to commercialization. The number of COVID-19 cases in South
Korea and the Philippines is more than 400,000.1

 

“Telcon and KPM Tech invested in
Humanigen with a view to increase involvement moving forward,” said Bob Atwill, Head of Asia-Pacific Region at Humanigen.
“This is the next step in our relationship and we are grateful for the support we have received. Humanigen’s expansion
strategy in the Asia-Pacific region is well underway and this is the first of other anticipated licensing transactions for lenzilumab
in COVID-19 hospitalised patients.”

 

About Humanigen, Inc. 

Humanigen,
Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via
its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing
platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company’s
immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious
cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies
using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company
is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various
eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through
the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or
natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or
treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally,
Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel)
in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com.

 

                                           

		1	The New York Times. Covid World Map: Tracking the Global Outbreak. Updated October 28, 2020. Accessed October 28, 2020. https://www.nytimes.com/interactive/2020/world/coronavirus-maps.html.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT J-2
	 	 	 

    	 

    

 

About KPM Tech Co., Ltd/Telcon
RF Pharmaceutical, Inc.

 

KPM Tech was established in
March 1971 to develop and manufacture plating chemicals, fully automatic plating equipment products, and associated technologies.
On January 7, 2003, KPM Tech was approved for registration and transaction on the KOSDAQ stock market of the Korea Exchange. Key
areas of focus include the manufacture and sale of PCBs, electronic communication semiconductors, surface treatment chemicals for
automobile parts, and fully automatic plating equipment. KPM Tech and its subsidiaries also develop pharmaceutical and biotechnology
products, including Opiranserin, an investigational non-narcotic analgesic that has completed a Phase 1/2a clinical trial in Korea.

 

Telcon was established in January
1999 to produce connectors, cable assemblies, etc. used in the manufacture of wireless communication equipment and today also manufactures
and commercializes pharmaceutical products. The company was listed on the KOSDAQ market on November 24, 2014 and major business
sectors include Telcon RF and pharmaceuticals/biotechnology. The pharmaceutical/biotechnology business division operates a Korea
Good Manufacturing Practice (KGMP) production facility to produce liquid formulation products and other formulations such as tablets,
pills, and capsules. There is also a continued investment in the development of new drugs.

 

Forward-Looking Statements

 

This release contains forward-looking
statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding
future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they
give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ
materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend,"
"plan," "potential," "possible," "goals," "accelerate," "continue,"
and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations
surrounding our operational, research, development or commercialization activities relating to lenzilumab in the Asia Pacific region,
our ability to achieve the US-based milestones to earn subsequent payments, and the ability of KPM Tech and Telcon to attain required
regulatory approvals in the covered territories for us to generate royalties based on their net sales of lenzilumab. Forward-looking
statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of
profitability and need for additional capital to grow our business; our dependence on partners to further the development of our
product candidates; the uncertainties inherent in the development, attainment of requisite regulatory approvals and launch of any
new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the
"Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT J-3
	 	 	 

    	 

    

 

All forward-looking statements
are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking
statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking
statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or
the occurrence of unanticipated events, except as required by law.

 

 

CONTACT:

Media

Cammy Duong

Westwicke, an ICR company

Cammy.Duong@Westwicke.com

203-682-8380

 

Investors

Alan Lada

Solebury Trout

alada@troutgroup.com

856-313-8206

 

 

* * * * *

 

    	CONFIDENTIAL
	LICENSE AGREEMENT
	EXHIBIT J-4
	 	 	 

    	 

    

 

EXHIBIT K: KEY TERMS OF SUPPLY AGREEMENT

 

		1.	Requirements Basis. HGEN or a HGEN Contract Manufacturer (as determined by HGEN) shall exclusively
supply Licensee’s requirements of the Licensed Product for the Licensed Indication.

 

		2.	Prices. [***].

 

		3.	Payment. 30 days after HGEN’s invoice. HGEN invoices to be issued on or after delivery
of the Licensed Product.

 

		4.	Delivery Point. EXW (INCOTERMS 2020) at the manufacturing site of the relevant HGEN Contract
Manufacturer (as determined by HGEN). Transportation and duties paid by Licensee.

 

		5.	Labeling & Packaging. HGEN standard labeling & packaging – prices to be adjusted
for other packaging.

 

		6.	Forecast Process. HGEN Contract Manufacturer requirement + 10 days.

 

		7.	Purchase Order Lead Time. HGEN Contract Manufacturer requirement + 10 days.

 

		8.	Minimum Order Quantity. HGEN Contract Manufacturer requirement.

 

		9.	Capacity Allocation. Manufacturing capacity for the Licensed Products shall be allocated
among licensees in the event of shortages by a process and formula determined by HGEN. [***].

 

		10.	Warranties.

		·	Licensed Product meets specifications at time of delivery.

		·	Licensed Product manufactured in compliance with cGMPs.

		·	Not less than 50% of remaining shelf life.

		·	Licensed Product clear of any liens or encumbrances.

		·	HGEN liability limited to purchase price of quantity delivered.

 

		11.	Stability Testing. By the relevant HGEN Contract Manufacturer (as determined by HGEN).

 

		12.	Manufacturing Transfer. HGEN may terminate the Supply Agreement after 7.5 years with technology
transfer to Licensee or a Licensee CMO.

 

 

* * * * *

 

 

	CONFIDENTIAL	LICENSE AGREEMENT	Exhibit K-1Exhibit
10.19

 

A COOPERATIVE
RESEARCH AND DEVELOPMENT AGREEMENT

 

 Between

 

Joint
Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense

 (JPEO-CBRND)

 (Laboratory)

 

Biomedical
Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response

 (BARDA)

 (Laboratory)

 

 and

 

 Humanigen

 (Cooperator)

 

Collectively Cooperators and Laboratories
are known as the “Parties” and each individually as a “Party.”

 

 

Article 1 Background

 

1.00 This Agreement is entered into under
the authority of the Federal Technology Transfer Act of 1986, 15 U.S.C. 3710a, et seq., between the Cooperator and the LaboratorIes,
the Parties to this Agreement.

 

1.01 JPEO-CBRND and BARDA, on behalf of
the U.S. Government, and Cooperator desire to collaborate in research and development on Lenzilumab, the “Product”
according to the attached Statement of Work (SOW) described in Appendix A. The benefit to the US government is developing a product
for potential response applications by demonstrating safety and efficacy in phase 3 clinical trials.

 

1.02 By providing consulting services and
subject matter expertise for manufacturing, regulatory, and statistical support and providing access to reserved manufacturing
capacity at Emergent Biosolutions (Baltimore, MD) related to the development and approval of the Product, the US government will
mitigate risk in the clinical trial, focus on treatment outcomes, and facilitate response use by generating pre-Emergency Use Authorization
submissions more efficiently.

 

1.03 NOW, THEREFORE, the Parties
agree as follows:

 

    	AGREEMENT# CAH5FS232001	1	Proprietary

    	 

    

 

Article 2 Definitions

 

2.00 The following terms
are defined for this Agreement as follows:

 

2.01 "Agreement" means this cooperative research and
development agreement, or CRADA.

 

2.02 "Invention" and "Made" have the meanings
set forth in Title 15 U.S.C. Section 3703(7) and (8).

 

2.03 “Product” shall mean lenzilumab, a monoclonal
antibody targeting GM-CSF for the treatment of COVID-19 pneumonia.

 

2.04 "Proprietary Information" means information marked
with a proprietary legend which embodies trade secrets developed at private expense or which is confidential business or financial
information, provided that such information:

 

 (i)       is not generally known, or which becomes generally known or available during the period of this Agreement from other sources without obligations concerning their confidentiality;

 

 (ii)     has not been made available by the owners to others without obligation concerning its confidentiality; and

 

 (iii)    is not already available to the receiving party without obligation concerning its confidentiality.

 

 (iv)    is not independently developed by or on behalf of the receiving party, without reliance on the information received hereunder.

 

 2.05 "Subject Data" means all recorded information first produced in the performance of this Agreement.

 

 2.06 "Subject Invention" means any Invention made as a consequence of the performance of work under this Agreement.

 

    	AGREEMENT# CAH5FS232001	2	Proprietary

    	 

    

 

Article 3 Research Scope and Administration

 

3.00 Statement of Work. Research performed under this
Agreement shall be performed in accordance with the SOW incorporated as a part of this Agreement at Appendix A. It is agreed that
any descriptions, statements, or specifications in the SOW shall be interpreted as goals and objectives of the services to be provided
under this Agreement and not requirements or warranties. Laboratories and Cooperator will endeavor to achieve the goals and objectives
of such services; however, each party acknowledges that such goals and objectives, or any anticipated schedule of performance,
may not be achieved.

 

3.01 Review of Work. Periodic conferences shall be held
between the Parties for the purpose of reviewing the progress of work. It is understood that the nature of this research is such
that completion within the period of performance specified, or within the limits of financial support allocated, cannot be guaranteed.
Accordingly, all research will be performed in good faith.

 

3.02 Product Manager. Any work required
by the Laboratories under the SOW will be performed under the supervision of Sheila Miknyoczki 200 C St SW Washington DC
20024; phone: 202-731-0362; Sheila.miknyoczki@hhs.gov ], who has responsibility
for the scientific and technical conduct of this project on behalf of the US government. Any work required by the Cooperator under
the SOW will be performed under the supervision of Cameron Durrant 533 Airport Blvd, Suite 400 Burlingame, CA 94010; phone:
908-672-9908; cdurrant@humanigen.com, who has responsibility for the scientific and technical
conduct of this project on behalf of the Cooperator.

 

3.03 Collaboration Changes. If at
any time the product managers determine that the research data dictates a substantial change in the direction of the work, the
Parties shall make a good faith effort to agree on any necessary change to the SOW and make the change by written notice to the
addresses listed in section 9.05 Notices.

 

3.04 Final Report. The Parties shall
prepare a final report of the results of this project within six months after completing the SOW.

 

 

Article 4 Ownership and Use of Physical
Property The parties will not transfer physical property. This agreement is for consulting services and technical support only
and requires only access to data. It does not cover the testing that generates the data. Any transfer of physical property will
occur under separate agreements.

 

 

Article 5 Subject Data and
Proprietary Information

 

5.00 Subject Data Ownership. This
agreement is for sharing data and consulting and technical support only. Any need to cover patent protection, intellectual property
cooperation, joint ownership, or US government access will be covered under separate agreements.

 

    	AGREEMENT# CAH5FS232001	3	Proprietary

    	 

    

 

5.01 Proprietary Information/Confidential
Information. Each party shall place a proprietary notice on all information it delivers to the other party under this Agreement
that it asserts is proprietary. The Parties agree that any Proprietary Information or Confidential Information furnished by one
party to the other party under this Agreement, or in contemplation of this Agreement, shall be used, reproduced and disclosed by
the receiving party only for the purpose of carrying out this Agreement, and shall not be released by the receiving party to third
parties unless consent to such release is obtained from the providing party.

 

5.02 Army limited-access database.
Notwithstanding anything to the contrary in this Article, the existence of established CRADAs specifying areas of research and
their total dollar amounts may be documented on limited access, password-protected websites of the JPEO-CBRND to provide a complete
picture of research efforts.

 

5.03 Information Release Restrictions and Public Affairs
for Both Parties. Except for disclosure and information required by the Securities and Exchange Commission (“SEC”),
the Parties agree to confer, review and approve prior to the public release of Subject Data and Proprietary Information as follows:

 

 (i)       Manuscript(s): Prior to any Party submitting a manuscript for publication which contains the results of the research under this Agreement, each party shall notify the other Parties in writing of the proposed manuscript, offer ample opportunity to review proposed manuscript, and to file patent applications in a timely manner (if applicable). Parties also agree to give appropriate credit to the entity responsible for research and development performed. This applies to information generated collaboratively.

 

 (ii)     Press releases, presentations, or other public releases of information: Prior to any such release containing the results or research performed under this Agreement Parties agree to provide written notification and ample opportunity for review. Comments and approval by each Party shall be prior to release, except that the Laboratories may release the name of the Cooperator and the title of the research for official government purposes without prior approval from the Cooperator. This applies to any press release, including those related to regulatory submissions, SEC filings, or any other press release.

 

 (iii)    Public Affairs and Operational Security Review: All manuscripts, press releases, presentations and other publications will be provided to the JPEOCBRND Public Affairs Office (PAO) and BARDA’s Communications Team allowing for thirty (30) days for review/approval prior to use or release. Per JPEO-CBRND regulation the PAO review will include Operational Security (OPSEC) review.

 

    	AGREEMENT# CAH5FS232001	4	Proprietary

    	 

    

 

 5.04 FDA Documents. This Agreement involves a product regulated by the U.S. Food and Drug Administration (FDA), the Parties authorize and consent to allow each other or their contractors or agents access to any documents filed with the FDA related to the product. Parties agree to include representatives from both Parties at all FDA regulatory meetings related to the Product.

 

 5.05 Clinical Specimens/Samples: If applicable: The Parties intend to collaborate in the conduct of future clinical trials. Rights and usage of any future clinical trial specimens and samples, and storage and usage rights, will be detailed in other Clinical Trial Agreements (CTAs) to be cross-referenced to this CRADA.

 

 

Article 6 Termination

 

6.00 Termination
by Mutual Consent. Parties may elect to terminate this Agreement, or portions thereof, at any time by mutual consent.

 

6.01 Termination
by Unilateral Action. Any party may unilaterally terminate this entire Agreement at any time by giving the other Parties written
notice, not less than 60 days prior to the desired termination date.

 

6.02 Termination
due to Subsequent Agreements. This agreement automatically terminates if a subsequent Contract or Other Transaction is awarded
that overlaps with any tasks in this CRADA.

 

6.03 Termination
Procedures. In the event of termination, the Parties shall specify the disposition of all property, patents and other results
of work accomplished or in progress, arising from or performed under this Agreement by written notice. Upon receipt of a written
termination notice, the Parties shall not make any new commitments and shall, to the extent feasible, cancel all outstanding commitments
that relate to this Agreement. Notwithstanding any other provision of this Agreement, any exclusive license entered into by the
Parties relating to this Agreement shall be simultaneously terminated unless the Parties agree to retain such exclusive license.

 

 

Article 7 Disputes

 

7.00 Settlement. Any dispute arising
under this Agreement which is not disposed of by agreement of the product managers shall be submitted jointly to the signatories
of this Agreement. A joint decision of the signatories or their designees shall be the disposition of such dispute, however; nothing
in this section shall prevent any party from pursuing any and all administrative and/or judicial remedies which may be allowable.

 

    	AGREEMENT# CAH5FS232001	5	Proprietary

    	 

    

 

Article 8 Liability

 

8.00 Property.
Neither party shall be responsible for damages to any property provided to, or acquired by, the other party pursuant to this Agreement.

 

8.01 Cooperator's
Employees. Cooperator agrees to indemnify and hold harmless the U.S. Government for liability of any kind involving an employee
of Cooperator arising in connection with this Agreement, and for all liabilities arising out of the use by Cooperator of Laboratories’
research and technical developments, or out of any use, sale or other disposition by Cooperator of products made based on Laboratories’
technical developments, except to the extent the liability is due to the negligence of Laboratories’ under the provisions
of the Federal Tort Claims Act or the Public Readiness and Emergency Preparedness Act. This provision shall survive termination
or expiration of this Agreement.

 

8.02 No
Warranty. The Parties make no express or implied warranty as to any matter whatsoever, including the conditions of the research
or any Invention or product, whether tangible or intangible, made, or developed under this Agreement, or the ownership, merchantability,
or fitness for a particular purpose of the research or any Invention or product.

 

 

Article 9 Miscellaneous

 

9.00 Governing Law. The construction,
validity, performance, and effect of this Agreement shall be governed for all purposes by the laws applicable to the United States
Government.

 

9.01 Export Control and Biological Select
Agents and Toxins. The obligations of the Parties to transfer technology to one or more other parties, provide technical information
and reports to one or more other parties, and otherwise perform under this Agreement are contingent upon compliance with applicable
United States export control laws and regulations. The transfer of certain technical data and commodities may require a license
from a cognizant agency of the United States Government or written assurances by the Parties that the Parties shall not export
technical data, computer software, or certain commodities to specified foreign countries without prior approval of an appropriate
agency of the United States Government. The Parties do not, alone or collectively, represent that a license shall not be required,
nor that, if required, it shall be issued. In addition, where applicable, the Parties agree to fully comply with all laws, regulations,
and guidelines governing biological select agents and toxins.

 

    	AGREEMENT# CAH5FS232001	6	Proprietary

    	 

    

 

9.02 Independent Contractors. The
relationship of the Parties to this Agreement is that of independent contractors and not as agents of each other or as joint venturers
or partners.

 

9.03 Use of Name or
Endorsements. (a) The Parties shall not use the name of the other Party on any product or service which is directly or
indirectly related to either this Agreement or any patent license or assignment agreement which implements this Agreement
without the prior approval of the other party, except use or reference of this CRADA and the Laboratories may be allowed
without written permission in the Cooperator’s required disclosures and filings with the Securities and Exchange
Commission (“SEC”) and other regulatory authorities . (b) By entering into this Agreement, The US government does
not directly or indirectly endorse any product or service provided, or to be provided, by Cooperator, its successors,
assignees, or licensees. Cooperator shall not in any way imply that this Agreement is an endorsement of any such product or
service. Press releases or other public releases of information shall be coordinated between the parties prior to release,
except that the Laboratories may release the name of the Cooperator and the title of the research without prior approval from
the Cooperator.

 

9.04 Survival of Specified
Provisions. The rights specified in provisions of this

Agreement covering, Proprietary Information,
Substitution for U.S. FDA Licensure, Transfer to Third Party, and Liability shall survive the termination or expiration of this
Agreement.

 

9.05 Notices. All notices pertaining
to or required by this Agreement shall be in writing and shall be signed by an authorized representative addressed as follows:

 

If to JPEO-CBRND: Dr. Clay Holloway

  JPEO-CBRND ORTA

  1564 Freedman Dr., Ft. Detrick,
MD, 21702

  Phone: 301-619-8513

  carl.c.holloway.civ@mail.mil

 

If to Cooperator: Cameron Durrant 

  533 Airport Blvd, Suite
400 Burlingame, CA 94010

  Phone: 908-672-9908

  cdurrant@humanigen.com

 

    	AGREEMENT# CAH5FS232001	7	Proprietary

    	 

    

 

If to Product Manager: Sheila Miknyoczki

  200 C St SW Washington DC 20024

  Phone: 202-731-0362

  Sheila.miknyoczki@hhs.gov

 

Any party may change such address by notice
given to the other in the manner set forth above.

 

9.06 Substitution for U.S. FDA Licensure.
(If applicable) To ensure the continued development and commercial availability of the products which the Parties will collaborate
to develop under this Agreement, Cooperator will notify JPEO-CBRND and BARDA in writing within 30 days of any Cooperator management
decision that Cooperator will not pursue U.S. FDA licensure of any such product and/or commercial marketing of such product as
originally agreed upon. If requested by JPEO-CBRND and BARDA within 10 days upon receipt of notice from the Cooperator, Cooperator
will transfer the IND, the Orphan Drug Status, the pre-Emergency Use Authorization submission, the Biologics License Application
(“BLA”) and all associated product/regulatory documentation related to such product to JPEO-CBRND regulatory offices.
If such material was developed by the Cooperator, the provision of this material to JPEO-CBRND will be upon fair and reasonable
terms negotiated in good faith between Cooperator and JPEO-CBRND. Provided that minimum compensation shall not be less than amounts
spent to date by Cooperator for the development of the Product. If such material was provided by JPEO-CBRND originally, such material
will be returned without negotiation or compensation.

 

9.07 Transfer to Third Party. Also
to ensure the continued development and commercial availability for the U.S. Government of these products which the Parties will
collaborate to develop under this Agreement, Cooperator will ensure that any transfer of the IND, EUA, or BLA for such products
to a third party will ensure that the third party is obligated to comply with paragraph 9.06 of this Agreement as if it were to
Cooperator.

 

 

Article 10 Duration of Agreement
and Effective Date

 

10.00 Effective Date. This Agreement
shall enter into force as of the date it is signed by the last authorized representative of the Parties.

 

10.01 Signature Execution. This Agreement
may be executed in one or more counterparts by the Parties by signature of a person having authority to bind the party, which may
be by facsimile signature, each of which when executed and delivered, by facsimile transmission, mail, or email delivery, will
be an original and all of which will constitute but one and the same agreement.

 

    	AGREEMENT# CAH5FS232001	8	Proprietary

    	 

    

 

10.02 Modification and Future Research.
It is the Parties intent that changes to the terms of this Agreement and/or additional agreed upon SOWs, to include future Clinical
Trials, will be added to this Agreement as written Notice of Modifications (NOMs). Original terms will remain in effect throughout
the NOMs unless otherwise stated and agreed upon.

 

10.03 Expiration Date. This Agreement
will automatically expire one (1) year from effective date unless it is revised by written notice and mutual agreement.

 

    	AGREEMENT# CAH5FS232001	9	Proprietary

    	 

    

 

IN WITNESS WHEREOF, the Parties have caused
this Agreement to be executed by their duly authorized representatives as follows:

 

 

 

	For JPEO-CBRND:	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	/s/ Douglas Bryce	 	DATE	1/21/2021	 
	 	NAME	 	 	 	 
	 	Mr. Douglas Bryce	 	 	 	 
	 	Joint Program Executive Officer for CBRN Defense	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	For BARDA:	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	/s/ Gary Disbrow	 	 	 	 
	 	NAME	 	DATE 	1/21/2021	 
	 	Dr. Gary Disbrow	 	 	 	 
	 	Director	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	For the Cooperator:	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	/s/ Cameron Durrant	 	DATE	1/21/2021	 
	 	NAME  	 	 	 	 
	 	Cameron Durrant	 	 	 	 
	 	Chairman and CEO, Humanigen	 	 	 	 

 

    	AGREEMENT# CAH5FS232001	10	Proprietary

    	 

    

 

 Proprietary

(CRADA)
APPENDIX A 

STATEMENT
OF WORK

 

 

Title: Consulting Services
for the development and manufacturing of Lenzilumab for COVID-19.

 

Background: Parties desire
to collaborate in clinical trials and manufacturing of the Product, Lenzilumab. The benefit to the US government is developing
a product for potential response applications by demonstrating safety and efficacy in clinical trials. By providing consulting
services and subject matter expertise for manufacturing, regulatory, and statistical support, and providing access to reserved
manufacturing capacity at Emergent Biosolutions (Baltimore, MD), the US government will mitigate risk in the clinical trial, focus
on treatment outcomes, and facilitate response use by generating pre-Emergency Use Authorization submissions more efficiently.

 

Collaboration:

 

US government agrees to:

 

		1.	Provide consulting services and subject matter expertise for manufacturing, regulatory, and statistical support in anticipation
of applying for Emergency Use Authorization (EUA) and eventually submitting a BLA.

 

		2.	Provide regulatory review and comments promptly on final drafts of submissions prior to submitting to FDA, including but not
limited to any request for Emergency Use Authorization under Section 564 of the Federal Food, Drug & Cosmetic Act and any biologics
license application under the provisions of §351(a) of the Public Health Service Act to permit use and marketing.

 

		3.	Provide regulatory representatives to participate in any formal or informal Sponsor meetings with the FDA.

 

		4.	Provide review of Public Law 115-92 Sponsor Authorization Letter prior to submission to the FDA.

 

		5.	Provide access to reserved manufacturing capacity for fill/finish activities at Emergent Biosolutions, Baltimore, MD (Camden).
The US government provides the reserved fill/finish slot.

 

    	AGREEMENT# CAH5FS232001	11	Proprietary

    	 

    

 

Cooperator agrees to:

 

		1.	Make available all data on performance of the Product in clinical trials.

 

		2.	Make available all correspondence with FDA (written, electronic, and telephonic) on the Product.

 

		3.	Make available all information related to current and planned manufacturing of the Product including production plans, scheduling,
and technical information.

 

		4.	Provide to Laboratories a letter to FDA indicating the Senior Director Medical Regulatory (SDMR) as a co-contact.

 

		5.	Provide to Laboratories top-line summaries and key conclusions supporting FDA regulatory filing.

 

		6.	Provide to Laboratories final drafts of FDA submissions for review prior to submitting to FDA, including but not limited to
any request for Emergency Use Authorization under Section 564 of the Federal Food, Drug & Cosmetic Act and any biologics license
application under the provisions of §351(a) of the Public Health Service Act to permit use and marketing.

 

		7.	Provide invitations for Laboratories regulatory representatives to participate in any formal or informal Sponsor meetings with
the FDA.

 

		8.	Provide to Laboratories all material communications and summaries thereof, both formal and informal, to or from FDA, regarding
the Product within 48 hours.

 

		9.	Provide Public Law 115-92 Sponsor Authorization Letter for Laboratory review prior to submission to the FDA; and upon Laboratory
approval, submit the letter to FDA.

 

 

	AGREEMENT# CAH5FS232001	12	Proprietary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]